

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## High-sensitivity C-reactive protein: an independent predictor of coronary heart disease risk in middle-aged and elderly population with hyperuricemia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028351
Article Type:	Research
Date Submitted by the Author:	04-Dec-2018
Complete List of Authors:	xie, mingsheng; Xiangya Hospital Central South University, Department of Orthopaedics Xie, Dongxing; Xiangya Hospital, Central South University, Department of Orthopaedics Ding, Xiang; Xiangya Hospital Central South University li, hui; Xiangya Hospital, Central South University, Department of Orthopaedics Yang, Ye; Xiangya Hospital Central South University, Department of Orthopaedics Zhang, Yi; Xiangya Hospital, Orthopaedics Li, Kun; Xiangya Hospital Central South University, Department of Orthopaedics Zhou, Bing; Hunan Key Laboratory of Joint Degeneration and Injury,
Keywords:	high-sensitivity C-reactive protein, hyperuricemia, coronary heart disease

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **High-sensitivity C-reactive protein: an independent predictor of coronary heart disease risk**  
5  
6  
7 **in middle-aged and elderly population with hyperuricemia**  
8  
9

10 Mingsheng Xie<sup>1†</sup>, Dongxing Xie<sup>1†</sup>, Ye Yang<sup>1</sup>, Yi Zhang<sup>1</sup>, Kun Li<sup>1</sup>, Bin Zhou<sup>1</sup>, Xiang Ding<sup>1\*</sup>, Hui  
11  
12  
13 Li<sup>1,2\*</sup>  
14  
15  
16  
17

18 <sup>1</sup> Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China;  
19

20 <sup>2</sup> Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, Hunan, China.  
21  
22  
23  
24

25 **Email address:** Mingsheng Xie<sup>1</sup>: Mingsheng-Xie2016@csu.edu.cn; Dongxing Xie:  
26  
27 xdx1024@csu.edu.cn; Ye Yang: 411859291@qq.com ; Yi Zhang: 57234919@qq.com ; Kun Li:  
28  
29 332845996@qq.com ; Bin Zhou: 673962793@qq.com ; Xiang Ding: dingxiang@csu.edu.cn; Hui Li<sup>2</sup>:  
30  
31 lihui1988@csu.edu.cn  
32  
33  
34  
35  
36  
37

38 **Correspondence to:** Hui Li, MD, PhD, Department of Orthopaedics, Xiangya Hospital, Central South  
39  
40 University, #87 Xiangya Road, Changsha, Hunan, China, E-mail: lihui1988@csu.edu.cn; **Xiang**  
41  
42 **Ding**, MD, PhD, Department of Orthopaedic, Xiangya Hospital, Central South University, #87  
43  
44 Xiangya Road, Changsha, Hunan, 410008, China. E-mail: dingxiang@csu.edu.cn.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

58  
59 <sup>1</sup> Mingsheng Xie and Dongxing Xie contributed equally to this article.

60 <sup>2</sup> Hui Li and Xiang Ding contributed equally to this article.

**Abstract**

**OBJECTIVES:** Hyperuricemia patients are at relatively high risk of developing coronary heart disease (CHD). The purpose of this study was to examine the relationship between high-sensitivity C-reactive protein (hs-CRP) and CHD risk in a middle-aged and elderly population with hyperuricemia.

**DESIGN:** A cross-sectional study.

**SETTING AND PARTICIPANTS:** This study was conducted in a health examination center of China. Participants diagnosed with hyperuricemia by the uric acid  $\geq 416 \mu\text{mol/L}$  in male population and  $\geq 360 \mu\text{mol/L}$  in female population were included.

**MAIN OUTCOME MEASURES:** 10-year CHD risk for each individual was evaluated using Framingham risk score based on the Adult Treatment Panel III charts.

**RESULTS:** A total of 517 hyperuricemia patients (438 males and 79 females) aged from 40 to 85 years old were included in the present study. 193 (37.3%) patients were defined with relatively high 10-year CHD risk. Compared with the lowest quintile, the crude odds ratio (ORs) of relatively high 10-year CHD risks were 2.05 (95%CI 1.14-3.67,  $P=0.016$ ), 2.77 (95%CI 1.54-4.98,  $P=0.001$ ), 2.12 (95%CI 1.18-3.80,  $P=0.012$ ) in the second, third and fifth quintiles of serum hs-CRP level, respectively ( $P$  for trend = 0.057). The multivariable-adjusted ORs of relatively high 10-year CHD risk were 2.05 (95%CI 1.13-3.72,  $P=0.019$ ) in the third, 2.69 (95%CI 1.47-4.89,  $P=0.001$ ) in the fourth, and 2.10 (95%CI 1.15-3.84,  $P=0.016$ ) in the fifth quintile of serum hs-CRP level when compared with the lowest quintile ( $P$  for trend = 0.068).

**CONCLUSION:** This study showed that high serum hs-CRP level was independently correlated with high CHD risk in middle-aged and elderly population with hyperuricemia, which suggested that serum

1  
2  
3  
4 hs-CRP, a routine index in clinical practice, may be used to predict CHD risk in hyperuricemia patients.  
5

6 **Key words:** hyperuricemia, high-sensitivity C-reactive protein, coronary heart disease  
7  
8  
9  
10  
11

### 12 **Strengths and limitations of this study**

- 13  
14 1. This is the first study exploring the association between hs-CRP and the CHD risk in patients with  
15  
16 hyperuricemia in a middle-aged and elderly population with hyperuricemia.  
17  
18 2. The relationship of hs-CRP and the CHD risk was analyzed by multivariable models.  
19  
20 3. As result of the nature of cross-sectional design, the causal relationship cannot be established in the  
21  
22 present study.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Background

Serum uric acid is the catabolic end-product of purine metabolism via the catalysis of xanthine oxidase. With the rapid economic development, the dietary habits of Chinese people have changed greatly towards an increasingly heavier intake of meat, dairy products and other purine enriched foods, which has led to a higher prevalence of hyperuricemia and gout susceptibility.<sup>1 2</sup> A systematic review and meta-analysis involving 44 studies showed that the pooled prevalence of hyperuricemia was 13.3% in mainland China from 2000 to 2014.<sup>3</sup> Some previous studies reported that an increase in serum uric acid was incriminated in the pathogenesis of metabolic syndrome,<sup>4 5</sup> chronic kidney disease,<sup>6 7</sup> stroke,<sup>8</sup> and coronary heart disease (CHD),<sup>9 10</sup>

Over the past several decades, relevant studies have shown that an increased serum uric acid was significantly associated with CHD, independent of conventional CHD risk factors.<sup>9-12</sup> Besides, it was also demonstrated that increased uric acid was correlated with hypertension, diabetes mellitus, metabolic syndrome, hypertriglyceridemia and endothelial dysfunction.<sup>6 13-19</sup> All of which could lead to an increased risk of CHD. With the trend of population aging, CHD has become one of the most common causes of death.<sup>20</sup> Therefore, it is urgent to seek effective predictors or biomarkers to identify subjects at a high risk of CHD, especially among the hyperuricemia patients, who are deemed a high risk group of CHD. A wide array of studies indicated that inflammation was involved in the pathogenesis of CHD.<sup>21 22</sup> C-reactive protein (CRP), one of the acute phase respondents, is commonly used in clinical practice to reflect chronic inflammation as an inexpensive measurement.<sup>23</sup> Several epidemiological studies were undertaken to clarify the relationship between CRP and CHD, but no agreement has been reached.<sup>24-26</sup> To the best of the authors' knowledge, there has been no study yet examining the association between

1  
2  
3  
4 hs-CRP and the CHD risk in hyperuricemia patients. Meaningful outcomes in this respect would not only  
5  
6 have important implications in understanding the pathophysiological mechanisms of CHD in  
7  
8 hyperuricemia patients, but also contribute to the development of a simple and inexpensive method to  
9  
10 predict the future CHD risk of this population.  
11  
12  
13  
14  
15  
16

17 To fill this knowledge gap, the present cross-sectional study was carried out to clarify the correlation  
18  
19 between hs-CRP and the 10-year estimated CHD risk measured by the Framingham risk score (FRS) in  
20  
21 the middle-aged and elderly population with hyperuricemia, with adjustment of conventional  
22  
23 cardiovascular risk factors.  
24  
25  
26  
27  
28  
29

## 30 **Materials and Methods**

### 31 **Study population**

32  
33 The participants of the present cross-sectional study were chosen from a pool of subjects who were  
34  
35 undergoing routine medical examinations at the Department of Health Examination Center Xiangya  
36  
37 Hospital, Central South University in Changsha, Hunan Province of China. The detailed methodology  
38  
39 has been described in some earlier studies.<sup>27-32</sup> Briefly, all the qualified participants must be 40 years  
40  
41 old or above and undergoing measurements of serum uric acid, hs-CRP and other basic biochemical  
42  
43 assessments during the specified period. In addition, the subjects should be diagnosed with  
44  
45 hyperuricemia (i.e., the uric acid  $\geq 416 \mu\text{mol/L}$  for male and  $\geq 360 \mu\text{mol/L}$  for female), with  
46  
47 availability of demographic and clinical data including age, gender, body mass index (BMI)  
48  
49 (weight/height<sup>2</sup>), smoking status, alcohol drinking status, activity level, medication status, etc. Initially,  
50  
51 a total of 5994 subjects were included based on the age requirement and availability of blood biochemical  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 assessments (serum uric acid and hs-CRP measurement) during the period of October 2013 to December  
5  
6 2015. Then, 3420 subjects were disqualified: 30 were lack of basic health characteristics such as blood  
7  
8 pressure and BMI; and 3390 were lack of information of health-related habits. Of the remaining 2574  
9  
10 subjects, only 517 were diagnosed with hyperuricemia and were finally enrolled in the present study.  
11  
12  
13  
14 The study protocol had been reviewed and approved by the local Ethics and Research Committee and  
15  
16 the written informed consent had been obtained from all participants prior to execution.  
17  
18  
19  
20  
21

### 22 **Blood biochemistry**

23  
24 All blood samples were drawn from the antecubital vein using vacuum tubes after an overnight fast of  
25  
26  $\geq 12$  hours, and were kept at 4°C until analysis. The hs-CRP was detected by the Latex turbidity method.  
27  
28  
29

30 The uric acid and other blood biochemical data were detected using a Beckman Coulter AU 5800  
31  
32 (Beckman Coulter Inc., Brea, CA, USA). The low concentrations (2.5 mmol/L for glucose and 118  
33  
34  $\mu\text{mol/L}$  for uric acid) and high concentrations (6.7 mmol/L for glucose and 472  $\mu\text{mol/L}$  for uric acid) of  
35  
36 standard human samples were used respectively to evaluate the intra- and inter-assay coefficients of  
37  
38 variation. The intra-assay coefficients of variation were 0.98% (2.5 mmol/L) and 1.72% (6.7 mmol/L)  
39  
40 for glucose, 1.39% (118  $\mu\text{mol/L}$ ) and 0.41% (472  $\mu\text{mol/L}$ ) for uric acid. The inter-assay coefficients of  
41  
42 variation were 2.45% (2.5 mmol/L) and 1.46% (6.7 mmol/L) for glucose, 1.40% (118  $\mu\text{mol/L}$ ) and 1.23%  
43  
44 (472  $\mu\text{mol/L}$ ) for uric acid. A subject was diagnosed with diabetes mellitus if his/her fasting plasma  
45  
46 glucose level  $\geq 7.0$  mmol/L or if he/she was currently receiving medication for blood glucose control.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

### 57 **Assessment of other exposures**

58  
59 The BMI was calculated as the weight (kg) divided by the square of the height (m). The blood pressure  
60



1  
2  
3  
4 was detected at the upper arm using an electronic sphygmomanometer after a rest of at least 10 min.  
5

6 Then, the status of physical activity, including the average frequency (never, one to two times per week,  
7  
8 three to four times per week, five times and above per week) and the average duration of physical activity  
9  
10 (within half an hour, half an hour to one hour, one to two hours, more than two hours) was collected from  
11  
12 each subject. Lastly, the smoking and alcohol drinking status, as well as the medication conditions of the  
13  
14 subjects were inquired.  
15  
16  
17  
18  
19  
20  
21

### 22 **Assessment of 10-year CHD risk**

23  
24 The risk level of developing CHD was measured by the FRS according to The Adult Treatment Panel III  
25  
26 (ATP III) charts,<sup>33</sup> and the FRS was calculated based on 7 risk factors, which are age, gender, smoking,  
27  
28 systolic blood pressure, use of antihypertensive medication, total cholesterol and HDL cholesterol,  
29  
30 respectively. The specific risk scoring process is as follows: 1) calculate the number of points for each  
31  
32 risk factor; 2) sum up the points of each risk factor to obtain the total risk score; 3) generate the estimated  
33  
34 10-year CHD risk for each patient. The subjects with the 10-year risk above 10% were classified into the  
35  
36 high 10-year CHD risk group.  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **Statistical analysis**

47  
48 For statistical analysis, the continuous variables with a normal distribution were presented as mean  $\pm$   
49  
50 standard deviation, and the category variables were described by frequency and percentage. The one-  
51  
52 way ANOVA (normally distributed data) or Kruskal-Wallis H test (non-normally distributed data) was  
53  
54 adopted to assess the continuous variables, while the  $\chi^2$  test was used to calculate the differences between  
55  
56 categorical variables. The participants were classified into five categories based on the quintile  
57  
58  
59  
60

1  
2  
3  
4 distribution of hs-CRP, namely  $\leq 0.50$ , 0.51-0.90, 0.91-1.63, 1.63-3.04, and  $\geq 3.05$  mg/L. The  
5  
6 association between hs-CRP and the CHD risk has been described as the odds ratio and 95% confidence  
7  
8 intervals, which were calculated for each quintile of hs-CRP; the lowest quintile was regarded as the  
9  
10 reference category. Then, the factors of BMI, educational background, alcohol drinking status, activity  
11  
12 level, serum creatinine and diabetes that might affect both hs-CRP and the outcomes of interest were  
13  
14 included in these models as adjusters. The trend for relatively high CHD risk according to quartile of hs-  
15  
16 CRP was analyzed using the linear regression model. All data analyses were performed using SPSS 18.0  
17  
18 (SPSS Inc., Chicago, IL, USA), and the level for statistical significance was set as the p-value equal to  
19  
20 0.05. All tests were two tailed.  
21  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **Results**

31  
32 A total of 517 hyperuricemia patients (438 males and 79 females) aged from 40 to 85 years old were  
33  
34 included in the present study. There were 193 (37.3%) patients were defined with relatively high  
35  
36 10-year CHD risk. The basic characteristics of study population based on the quintiles of hs-CRP  
37  
38 were showed in Table 1. Significant differences across all quintiles of hs-CRP were observed in  
39  
40 terms of BMI, relatively high CHD risk, systolic blood pressure, diastolic blood pressure, activity  
41  
42 level, and educational background.  
43  
44  
45  
46  
47  
48  
49  
50

51 The results of the associations between hs-CRP and relatively high 10-year CHD risk ( $\geq 10\%$ )  
52  
53 were shown in Table 2. According to the crude OR values, a significant higher prevalence of  
54  
55 relatively high CHD risk was observed in the third (OR=2.05, 95%CI 1.14-3.67, P=0.016), fourth  
56  
57 (OR=2.77, 95%CI 1.54-4.98, P=0.001) and highest quintiles (OR=2.12, 95%CI 1.18-3.80, P=0.012)  
58  
59  
60

1  
2  
3  
4 of hs-CRP when comparing with the reference category, and P for trend was 0.057. Multivariable  
5  
6 adjusted OR value also suggested that hs-CRP was positively associated with relatively high 10-  
7  
8 year CHD risk in the third (OR=2.05, 95%CI 1.13-3.72, P=0.019), fourth (OR=2.69, 95%CI 1.47-  
9  
10 4.89, P=0.001) and highest quintiles (OR=2.10, 95%CI 1.15-3.84, P=0.016) of hs-CRP when  
11  
12 comparing with the reference category, and P for trend was 0.068.  
13  
14  
15  
16  
17  
18  
19

## 20 Discussion

21  
22 The present cross-sectional study revealed a significant positive association between hs-CRP and the  
23  
24 high 10-year risk of CHD in the middle-aged and elderly population with hyperuricemia. This correlation  
25  
26 remained significant with adjustment of several potential confounding factors such as BMI, educational  
27  
28 background, alcohol drinking status, activity level, serum creatinine and diabetes. These findings  
29  
30 suggested that hs-CRP could serve as a marker for the risk of CHD in hyperuricemia patients.  
31  
32  
33  
34  
35  
36  
37

38 The relationship between CRP and CHD has aroused intensive arguments. Some earlier studies  
39  
40 demonstrated that a high level of CRP concentration was positively associated with CHD, and that CRP  
41  
42 was predictive of CHD.<sup>34-37</sup> For example, in two nested case-control studies — the Nurses' Health Study  
43  
44 and the Health Professionals Follow-up Study — Jennifer et al. found that a high level of CRP was  
45  
46 associated with an increased risk of CHD among participants with no history of cardiovascular disease  
47  
48 and that the level of CRP could be considered as a predictor of CHD.<sup>38</sup> In the Cardiovascular Health  
49  
50 Study, elevated CRP was found to be associated with an increased 10-year risk of CHD, regardless of  
51  
52 the presence of conventional risk factors.<sup>39</sup> Besides, a cross-sectional study conducted in Japan  
53  
54 demonstrated that hs-CRP was associated with the estimated risk level of CHD in the middle-aged men.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 <sup>40</sup> However, controversy remains with respect to the association of CRP with CHD, and the predictive  
5  
6 value of CRP. According to the data obtained from the MONICA Optional Haemostasis Study, no  
7  
8 significant correlation was observed between the CHD event rate and the plasma CRP in the European  
9  
10 populations. <sup>41</sup> Similarly, it was shown that the CRP level was not significantly associated with CHD  
11  
12 with adjustment of conventional risk factors in the post-menopausal women. <sup>42</sup> Meanwhile, the findings  
13  
14 from the 1999–2004 NHANES suggested that hs-CRP was not associated with the CHD mortality. <sup>43</sup>  
15  
16 The present study further revealed that CRP was positively associated with CHD in patients with  
17  
18 hyperuricemia.  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Previous in vivo and in vitro studies have suggested that CRP modulated many factors involved in  
29  
30 atherosclerosis, which might explain the positive association between the CRP level and CHD. CRP  
31  
32 could reduce the endothelial nitric oxide synthase both at the protein and mRNA levels and promote the  
33  
34 production of inducible nitric oxide synthase and endothelin-1 in endothelial cells. <sup>38 39</sup> Besides, it was  
35  
36 reported that the adhesion and internalization of white blood cells onto the arterial wall were improved  
37  
38 by CRP by inducing the expression of vascular cell adhesion molecule-1, intercellular adhesion  
39  
40 molecule-1, E-selectin, and monocyte chemoattractant protein-1. <sup>44 45</sup> Moreover, CRP could also induce  
41  
42 the monocyte chemotaxis and differentiation, <sup>46 47</sup> and facilitate the uptake of oxidized low-density  
43  
44 lipoprotein through macrophages and monocyte-platelets aggregation. <sup>48 49</sup> Further evidence supported  
45  
46 CRP as a participant in later stages of atherosclerosis with the expression of matrix metalloproteinases  
47  
48 and collagenase activity in human monocyte-macrophages. <sup>50 51</sup>  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The present study clarified that high hs-CRP was correlated with a high CHD risk in the middle-

1  
2  
3  
4 aged and elderly population with hyperuricemia. It is suggested that hyperuricemia interacts  
5  
6 synergistically with high hs-CRP subjects, and may subsequently enhance the risk of CHD predictor  
7  
8 value of hs-CRP. This has implications for clinicians to predict the CHD risk in hyperuricemia patients  
9  
10 based on hs-CRP, a frequently used biomarker, and thereby providing preventive measures accordingly.  
11  
12  
13  
14 Meanwhile, it also prompts that uric acid may interact with other risk factors during the development  
15  
16 and progression of CHD, but such conclusion needs to be validated by further study.  
17  
18  
19  
20  
21  
22

23 Several strengths and shortcomings of this study are worth mentioning. First, this is the first study  
24  
25 exploring the association between hs-CRP and the CHD risk in patients with hyperuricemia in the  
26  
27 middle-aged and elderly population. Second, multivariable models were used to analyze the  
28  
29 aforementioned relationship by adjusting a considerable number of potential confounding factors, such  
30  
31 as BMI, serum creatinine and diabetes. As for the limitation, no causal relationship can be established in  
32  
33 the present study due to the nature of cross-sectional design. However, the primary objective of this study  
34  
35 was to examine the association between CRP and the CHD risk rather than to prove that CRP could  
36  
37 increase the incidence of CHD. As CRP was deemed to be correlated with the CHD risk score, it can be  
38  
39 used to reflect this complicated index in clinical practice. Subsequently, other more complicated indexes  
40  
41 such as the Framingham risk score could be used to examine the CHD risk. Therefore, it can be  
42  
43 speculated that CRP could be taken as an easily accessible screening method.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

#### 54 **Conclusion**

55  
56 This study showed that high serum hs-CRP level was independently correlated with high CHD risk in  
57  
58 middle-aged and elderly population with hyperuricemia, which suggested that serum hs-CRP, a routine  
59  
60

1  
2  
3  
4 index in clinical practice, may be used to predict CHD risk in hyperuricemia patients.  
5  
6  
7  
8

9 **Contributors** MX, DX, HL and XD were responsible for the conception and design of the study. KL  
10 and BZ contributed to the statistical analyses. MX, DX, HL, XD, YY and YZ contributed to the data  
11 collection and interpretation. MX, DX, HL and XD drafted the manuscript. HL and XD contributed to  
12 the revision of the manuscript. All authors read and approved the final manuscript.  
13  
14  
15  
16  
17  
18

19 **Funding** This work was supported by the National Natural Science Foundation of China (81772413,  
20 81702207, 81702206), the Young Investigator Grant of Xiangya Hospital, Central South University  
21 (2017Q10), and the Postgraduate Independent Exploration and Innovation Project of Central South  
22 University (2018zzts256).  
23  
24  
25  
26  
27  
28

29 **Competing interests** None declared.  
30  
31

32 **Patient consent** Not required.  
33  
34  
35

36 **Ethics approval** This study was approved by the ethics committee of Xiangya Hospital, Central South  
37 University.  
38  
39

40 **Data sharing statement:** No additional data available.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**References:**

1. Hak AE, Choi HK. Lifestyle and gout. *Current Opinion in Rheumatology* 2008;20:179-86.
2. Zhai FY, He YN, Ma GS, et al. [Study on the current status and trend of food consumption among Chinese population]. *Chinese Journal of Epidemiology* 2005;26:485.
3. Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. *Biomed Research International* 2015;2015:762820.
4. Onat A, Uyarel H, Hergenç G, et al. Serum Uric Acid Is a Determinant of Metabolic Syndrome in a Population-Based Study. *American Journal of Hypertension* 2006;19:1055-62.
5. Oda E. Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population. *Heart & Vessels* 2014;29:496-503.
6. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. *American Journal of Kidney Diseases* 2004;44:642-50.
7. Chang HY, Tung CW, Lee PH, et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. *American Journal of the Medical Sciences* 2010;339:509-15.
8. Li M, Hou W, Zhang X, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. *Atherosclerosis* 2014;232:265-70.
9. Lai X, Yang L, Légaré S, et al. Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji Cohort. *International Journal of Cardiology* 2016;224:299-304.
10. Braga F, Pasqualetti S, Ferraro S, et al. Hyperuricemia as risk factor for coronary heart disease

1  
2  
3  
4 incidence and mortality in the general population: a systematic review and meta-analysis. *Clinical*  
5  
6  
7 *Chemistry & Laboratory Medicine* 2016;54:7-15.

8  
9 11. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: A systematic review  
10  
11 and meta - analysis. *Arthritis Care & Research* 2010;62:170-80.

12  
13 12. Coutinho TDA, Turner ST, Peysers PA, et al. Associations of Serum Uric Acid With Markers of  
14  
15 Inflammation, Metabolic Syndrome, and Subclinical Coronary Atherosclerosis. *American Journal of*  
16  
17 *Hypertension* 2007;20:83-9.

18  
19 13. Perlstein TS, Gumieniak O, Williams GH, et al. Uric Acid and the Development of Hypertension  
20  
21 The Normative Aging Study. *Hypertension* 2006;48:1031-36.

22  
23 14. Li Q, Yang Z, Lu B, et al. Serum uric acid level and its association with metabolic syndrome and  
24  
25 carotid atherosclerosis in patients with type 2 diabetes. *Cardiovascular Diabetology* 2011;10:1-7.

26  
27 15. Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations  
28  
29 predict subsequent weight gain and blood pressure elevation. *Hypertension* 2003;42:474-80.

30  
31 16. Nakanishi N, Okamoto M, Yoshida H, et al. Serum Uric Acid and Risk for Development of  
32  
33 Hypertension and Impaired Fasting Glucose or Type II Diabetes in Japanese Male Office Workers.  
34  
35 *European Journal of Epidemiology* 2003;18:523-30.

36  
37 17. Dehghan A, Hoek MV, Sijbrands EJG, et al. High Serum Uric Acid as a Novel Risk Factor for Type  
38  
39 2 Diabetes. *Diabetes Care* 2008;31:361-2.

40  
41 18. Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components  
42  
43 of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery  
44  
45 Risk Development in Young Adults. *Annals of Epidemiology* 1998;8:250-61.

46  
47 19. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. *Kidney*  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 *International* 2005;67:1739-42.

5  
6  
7 20. Lloyd-Jones. Heart Disease and Stroke Statistics-2009 Update: A Report From the American Heart  
8  
9 Association Statistics Committee and Stroke Statistics Subcommittee (vol 119, pg e21, 2009).  
10  
11 *Circulation* 2011;124:E424.

12  
13  
14 21. Libby P, Sukhova G, Lee RT, et al. Cytokines regulate vascular functions related to stability of the  
15  
16 atherosclerotic plaque. *J Cardiovasc Pharmacol* 1995;25 Suppl 2:S9.

17  
18  
19 22. Ross R. Atherosclerosis-inflammatory disease. *N Engl J Med* 1999;340.

20  
21  
22 23. Savve VD, Ushakov GS. C-reactive protein, a sensitive marker for inflammation, predicts future risk  
23  
24 of coronary heart disease in initially healthy middle-aged men: Koenig W, Sund M, Frohlich M, et al:  
25  
26 *Circulation* 99: 237 - 242, 1999. *Zhurnal Mikrobiologii Epidemiologii I Immunobiologii* 1962;33:15-20.

27  
28  
29 24. Yarnell J, Mccrum E, Rumley A, et al. Association of European population levels of thrombotic and  
30  
31 inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study†.  
32  
33 *European Heart Journal* 2005;26:332-42.

34  
35  
36 25. Otsuka T, Kawada T, Katsumata M, et al. High-sensitivity C-reactive protein is associated with the  
37  
38 risk of coronary heart disease as estimated by the Framingham Risk Score in middle-aged Japanese men.  
39  
40  
41  
42  
43 *International Journal of Cardiology* 2008;129:245-50.

44  
45  
46 26. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of  
47  
48 inflammation in the prediction of coronary heart disease. *Acc Current Journal Review* 2004;13:27-8.

49  
50  
51 27. Zeng C, Li H, Wei J, et al. Association between Dietary Magnesium Intake and Radiographic Knee  
52  
53 Osteoarthritis. *Plos One* 2015;10: e0127666.

54  
55  
56 28. Zeng C, Wei J, Li H, et al. Relationship between Serum Magnesium Concentration and Radiographic  
57  
58 Knee Osteoarthritis. *Journal of Rheumatology* 2015;42:1231-6.

- 1  
2  
3  
4 29. Zeng C, Wang YL, Wei J, et al. Association between low serum magnesium concentration and  
5  
6 hyperuricemia. *Magnesium Research Official Organ of the International Society for the Development of*  
7  
8  
9 *Research on Magnesium* 2015;28:56.  
10  
11  
12 30. Xie DX, Xiong YL, Zeng C, et al. Association between low dietary zinc and hyperuricaemia in  
13  
14 middle-aged and older males in China: a cross-sectional study. *BMJ Open* 2015;5:e008637.  
15  
16  
17 31. Xiong Y, Wei J, Zeng C, et al. Association between dietary iron intake and bone mineral density: A  
18  
19 cross-sectional study in Chinese population. *Nutrition & Dietetics* 2016;73:433-40.  
20  
21  
22 32. Li H, Zeng C, Wei J, et al. Associations between dietary antioxidants intake and radiographic knee  
23  
24 osteoarthritis. *Clinical Rheumatology* 2016;35:1585-92.  
25  
26  
27 33. Program NCE. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel  
28  
29 on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel  
30  
31 III) final report. *Circulation* 2002;106:3143-421.  
32  
33  
34 34. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary  
35  
36 heart disease in older men and women: the cardiovascular health study. *Circulation* 2005;112:25-31.  
37  
38  
39 35. Straczek C, Ducimetiere P, Barbergergateau P, et al. Higher level of systemic C-reactive protein is  
40  
41 independently predictive of coronary heart disease in older community-dwelling adults: the three-city  
42  
43 study. *Journal of the American Geriatrics Society* 2010;58:129-35.  
44  
45  
46 36. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of  
47  
48 inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004;350:1387-97.  
49  
50  
51 37. Kaptoge S, Angelantonio ED, Lowe G, et al. C-reactive protein concentration and risk of coronary  
52  
53 heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* 2010;375:132-40.  
54  
55  
56 38. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration That C-Reactive Protein Decreases eNOS  
57  
58  
59  
60

- 1  
2  
3  
4 Expression and Bioactivity in Human Aortic Endothelial Cells. *Circulation* 2002;106:1439-41.  
5  
6  
7 39. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate  
8  
9 the proatherogenic effects of C-reactive protein. *Circulation* 2002;105:1890.  
10  
11  
12 40. Otsuka T, Kawada T, Katsumata M, et al. High-sensitivity C-reactive protein is associated with the  
13  
14 risk of coronary heart disease as estimated by the Framingham Risk Score in middle-aged Japanese men.  
15  
16  
17 *International Journal of Cardiology* 2008;129:245.  
18  
19  
20 41. Yarnell J, Mccrum E, Rumley A, et al. Association of European population levels of thrombotic and  
21  
22 inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study.  
23  
24  
25 *European Heart Journal* 2005;26:332-42.  
26  
27  
28 42. Kim HC, Greenland PRossouw JE, Manson JE, et al. Multimarker prediction of coronary heart  
29  
30 disease risk: the Women's Health Initiative. *Journal of the American College of Cardiology*  
31  
32 2010;55:2080-91.  
33  
34  
35 43. Veeranna V, Zalawadiya SK, Panaich S, et al. Comparative analysis of red cell distribution width  
36  
37 and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic  
38  
39 population: findings from the 1999-2004 NHANES. *International Journal of Cardiology*  
40  
41 2013;168:5156-61.  
42  
43  
44  
45  
46 44. Pasceri V, Willerson JT, Yeh ET, et al. Direct proinflammatory effect of C-reactive protein on human  
47  
48 endothelial cells. *Circulation* 2000;102:2165-8.  
49  
50  
51 45. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte  
52  
53 chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. *Circulation*  
54  
55 2001;103:2531-4.  
56  
57  
58  
59 46. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive  
60

1  
2  
3  
4 protein receptor-dependent monocyte recruitment in atherogenesis. *Arteriosclerosis Thrombosis &*  
5  
6  
7 *Vascular Biology* 2000;20:2094.

8  
9 47. Zhang R, Becnel L, Li M, et al. C-reactive protein impairs human CD14+ monocyte-derived dendritic  
10  
11 cell differentiation, maturation and function. *European Journal of Immunology* 2006;36:2993-3006.

12  
13  
14 48. Chang MK, Binder CJ, Torzewski M, et al. C-reactive protein binds to both oxidized LDL and  
15  
16 apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids.  
17  
18  
19 *Proceedings of the National Academy of Sciences of the United States of America* 2002;99:13043-48.

20  
21  
22 49. Zwaka TP, Hombach V, Torzewski J, et al. C-reactive protein-mediated low density lipoprotein  
23  
24 uptake by macrophages: implications for atherosclerosis. *Circulation* 2001;103:1194-7.

25  
26  
27 50. Williams TN, Zhang CX, Game BA, et al. C-Reactive Protein Stimulates MMP-1 Expression in  
28  
29 U937 Histiocytes Through Fc  $\gamma$  RII and Extracellular Signal-Regulated Kinase Pathway: An Implication  
30  
31 of CRP Involvement in Plaque Destabilization. *Arterioscler Thromb Vasc Biol* 2004;24:61-6.

32  
33  
34 51. Nabata A, Kuroki M, Ueba H, et al. C-reactive protein induces endothelial cell apoptosis and matrix  
35  
36 metalloproteinase-9 production in human mononuclear cells: Implications for the destabilization of  
37  
38 atherosclerotic plaque. *Atherosclerosis* 2008;196:129.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 Basic characteristics of study population based on the quintiles of hs-CRP level (n=517)

Characteristics	Quintiles of hs-CRP					P#
	1 (lowest)	2	3	4	5 (highest)	
N	108	99	106	100	104	
Age (years)	50.2 (6.6)	50.2 (5.6)	51.3 (7.3)	51.4 (6.0)	51.5 (7.4)	0.314
Female (%)	13.0	13.1	13.2	19.0	18.3	0.568
BMI (kg/m <sup>2</sup> )	25.3 (3.2)	26.0 (2.6)	26.8 (3.1)	26.8 (3.0)	27.0 (3.6)	0.001
Relatively high CHD risk (≥10%, %)	25.0	32.3	40.6	48.0	41.3	0.007
Total cholesterol (mg/dl)	202.8 (35.6)	209.1 (37.9)	207.8 (40.9)	211.1 (41.4)	206.7 (49.6)	0.683
HDL cholesterol (mg/dl)	53.2 (13.4)	51.6 (13.5)	51.8 (9.6)	50.7 (12.1)	49.5 (10.6)	0.308
Systolic blood pressure (mmHg)	129.4 (14.3)	132.7 (15.7)	133.6 (15.5)	135.6 (16.9)	136.3 (17.4)	0.023
Diastolic blood pressure (mmHg)	82.1 (11.0)	84.3 (11.5)	85.1 (11.3)	86.3 (11.6)	87.5 (12.2)	0.006
Diabetes (yes, %)	12.0	12.1	11.3	18.0	17.3	0.476
Activity level (h/week)	2.0 (2.5)	1.3 (2.3)	1.8 (2.9)	1.6 (2.7)	1.2 (2.3)	0.015
Smoking (yes, %)	24.1	29.3	34.9	36.0	35.6	0.266
Alcohol drinking (yes, %)	53.7	61.6	63.2	61.0	52.9	0.407
Educational background (High school or above, %)	66.7	53.5	75.5	66.0	62.5	0.024
Serum creatinine	100.5 (32.8)	104.4 (49.7)	98.9 (14.9)	99.5 (34.9)	99.1 (17.6)	0.663

Data are mean (standard deviation), unless otherwise indicated; hs-CRP, hypersensitive C-reactive protein; BMI, body mass index; HDL, high density lipoprotein.

# P values are for test of difference across all quintiles of hs-CRP.

Table 2 Associations between hs-CRP and relatively high 10-year CHD risk ( $\geq 10\%$ ) in hyperuricemia population (n=517)

	Quintiles of hs-CRP					P for trend
	1 (lowest)	2	3	4	5 (highest)	
Participants (n)	108	99	106	100	104	
Median hs-CRP (mg/L)	0.34	0.69	1.21	2.11	6.12	
Crude OR (95%CI)	1.00 (reference)	1.43 (0.78, 2.63)	2.05 (1.14, 3.67)	2.77 (1.54, 4.98)	2.12 (1.18, 3.80)	0.057
P values	-	0.245	0.016	0.001	0.012	
Multivariable adjusted OR (95% CI)	1.00 (reference)	1.40 (0.75, 2.61)	2.05 (1.13, 3.72)	2.69 (1.47, 4.89)	2.10 (1.15, 3.84)	0.068
P values	-	0.291	0.019	0.001	0.016	

\*Multivariable adjusted model was adjusted for BMI, educational background, alcohol drinking status, activity level, serum creatinine and diabetes. hs-CRP, hypersensitive C-reactive protein; CHD, coronary heart disease; OR, odds ratio; CI, confidence interval.

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4,5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5, 6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5,6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7, 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7, 8
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	7,8

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	5, 6
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	19
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8,9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	19
		(b) Report category boundaries when continuous variables were categorized	20
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	20
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9,10,11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## High-sensitivity C-reactive protein, an independent predictor of coronary heart disease risk in middle-aged and elderly Chinese population with hyperuricemia: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028351.R1
Article Type:	Original research
Date Submitted by the Author:	27-Jun-2019
Complete List of Authors:	Xie, Mingsheng; Xiangya Hospital Central South University, Department of Orthopaedics Xie, Dongxing; Xiangya Hospital, Central South University, Department of Orthopaedics Yang, Ye; Xiangya Hospital Central South University, Department of Orthopaedics Zhang, Yi; Xiangya Hospital, Orthopaedics Li, Kun; Xiangya Hospital Central South University, Department of Orthopaedics Zhou, Bin; Xiangya Hospital Central South University, Department of Orthopaedics Yang, Zidan; Xiangya School of Public Health, Central South University, Department of Epidemiology and Health Statistics Ding, Xiang; Xiangya Hospital Central South University Li, Hui; Xiangya Hospital, Central South University, Department of Orthopaedics
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	high-sensitivity C-reactive protein, hyperuricemia, Coronary heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 1 **High-sensitivity C-reactive protein, an independent predictor of coronary heart disease risk**  
5  
6 2 **in middle-aged and elderly Chinese population with hyperuricemia: a cross-sectional study**  
7  
8  
9

10 3 Mingsheng Xie<sup>1</sup>†, Dongxing Xie<sup>1</sup>†, Ye Yang<sup>1</sup>, Yi Zhang<sup>1</sup>, Kun Li<sup>1</sup>, Bin Zhou<sup>1</sup>, Zidan Yang,<sup>2</sup> Xiang  
11  
12  
13 4 Ding<sup>1</sup>\*, Hui Li<sup>1,3</sup>\*

14  
15  
16  
17  
18 5 <sup>1</sup> Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China;

19  
20 6 <sup>2</sup> Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South  
21  
22  
23 7 University, Changsha, Hunan, China; <sup>3</sup> Hunan Key Laboratory of Joint Degeneration and Injury,  
24  
25  
26 8 Changsha, Hunan, China.

27  
28  
29  
30 9 **Email address:** Mingsheng Xie<sup>1</sup>: Mingsheng-Xie2016@csu.edu.cn; Dongxing Xie:  
31  
32  
33 10 xdx1024@csu.edu.cn; Ye Yang: 411859291@qq.com; Yi Zhang: 57234919@qq.com; Kun Li:  
34  
35  
36 11 332845996@qq.com; Bin Zhou: 673962793@qq.com; Xiang Ding: dingxiang@csu.edu.cn; Hui Li<sup>2</sup>:  
37  
38  
39 12 lihui1988@csu.edu.cn

40  
41  
42  
43 13 **Correspondence to:** Hui Li, MD, PhD, Department of Orthopaedics, Xiangya Hospital, Central South  
44  
45  
46 14 University, #87 Xiangya Road, Changsha, Hunan, China, E-mail: lihui1988@csu.edu.cn; **Xiang**  
47  
48 15 **Ding**, MD, PhD, Department of Orthopaedic, Xiangya Hospital, Central South University, #87  
49  
50  
51 16 Xiangya Road, Changsha, Hunan, 410008, China. E-mail: dingxiang@csu.edu.cn.

52  
53 17  
54  
55 18

56  
57  
58  
59 

---

<sup>1</sup> Mingsheng Xie and Dongxing Xie contributed equally to this article.

60 <sup>2</sup> Hui Li and Xiang Ding contributed equally to this article.

1

2 **Abstract**

3 **OBJECTIVES:** Hyperuricemia patients are at relatively high risk of developing coronary heart disease  
4 (CHD). The purpose of this study was to examine the relationship between high-sensitivity C-reactive  
5 protein (hs-CRP) and CHD risk in a middle-aged and elderly population with hyperuricemia.

6 **DESIGN:** A cross-sectional study.

7 **SETTING AND PARTICIPANTS:** This study was conducted in a health examination center of China.  
8 Participants were diagnosed with hyperuricemia based on uric acid concentrations. Specifically, males  
9 with a uric acid concentration  $\geq 416$   $\mu\text{mol/L}$  were included, as well as females with a concentration  $\geq$   
10 360  $\mu\text{mol/L}$ .

11 **MAIN OUTCOME MEASURES:** 10-year CHD risk for each individual was evaluated using  
12 Framingham risk score based on the Adult Treatment Panel III charts.

13 **RESULTS:** A total of 517 hyperuricemia patients (438 males and 79 females) aged from 40 to 85 years  
14 old were included in the present study. 193 (37.3%) patients were defined with relatively high 10-year  
15 CHD risk. Compared with the lowest quintile, the crude odds ratio (ORs) of relatively high 10-year CHD  
16 risks were 2.05 (95%CI 1.14-3.67,  $P=0.016$ ), 2.77 (95%CI 1.54-4.98,  $P=0.001$ ), 2.12 (95%CI 1.18-3.80,  
17  $P=0.012$ ) in the third, fourth and fifth quintiles of serum hs-CRP level, respectively ( $P$  for trend = 0.057).

18 The multivariable-adjusted ORs of relatively high 10-year CHD risk were 2.05 (95%CI 1.13-3.72,  
19  $P=0.019$ ) in the third, 2.69 (95%CI 1.47-4.89,  $P=0.001$ ) in the fourth, and 2.10 (95%CI 1.15-3.84,  
20  $P=0.016$ ) in the fifth quintile of serum hs-CRP level when compared with the lowest quintile ( $P$  for trend  
21 = 0.068).

22 **CONCLUSION:** This study showed that there was a borderline association between high serum hs-CRP

1  
2  
3  
4 1 level and high CHD risk in middle-aged and elderly population with hyperuricemia, which suggested  
5  
6 2 that serum hs-CRP, a routine index in clinical practice, may be used to predict CHD risk in hyperuricemia  
7  
8  
9 3 patients.

10  
11 4 **Key words:** hyperuricemia, high-sensitivity C-reactive protein, coronary heart disease  
12  
13  
14  
15  
16

17 7 **Strengths and limitations of this study**

- 18  
19  
20 8 1. This is the first study exploring the association between hs-CRP and the CHD risk in patients with  
21  
22 9 hyperuricemia in a middle-aged and elderly population with hyperuricemia.  
23  
24  
25 10 2. The relationship of hs-CRP and the CHD risk was analyzed by multivariable models.  
26  
27 11 3. As result of the nature of cross-sectional design, the causal relationship cannot be established in the  
28  
29 12 present study.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 **Background**

2 Serum uric acid is the catabolic end-product of purine metabolism via the catalysis of xanthine oxidase.  
3 With the rapid economic development, the dietary habits of Chinese people have changed greatly towards  
4 an increasingly heavier intake of meat, dairy products and other purine enriched foods, which has led to  
5 a higher prevalence of hyperuricemia and gout susceptibly.<sup>1 2</sup> A systematic review and meta-analysis  
6 involving 44 studies showed that the pooled prevalence of hyperuricemia was 13.3% in mainland China  
7 from 2000 to 2014.<sup>3</sup> Some previous studies reported that an increase in serum uric acid was incriminated  
8 in the pathogenesis of metabolic syndrome,<sup>4 5</sup> chronic kidney disease,<sup>6 7</sup> stroke,<sup>8</sup> and coronary heart  
9 disease (CHD).<sup>9 10</sup>

10  
11 Over the past several decades, relevant studies have shown that an increased serum uric acid was  
12 significantly associated with CHD, independent of conventional CHD risk factors.<sup>9-12</sup> Besides, it was  
13 also demonstrated that increased uric acid was correlated with hypertension, diabetes mellitus, metabolic  
14 syndrome, hypertriglyceridemia and endothelial dysfunction.<sup>6 13-19</sup> All of which could lead to an  
15 increased risk of CHD. With the trend of population aging, CHD has become one of the most common  
16 causes of death.<sup>20</sup> Therefore, it is urgent to seek effective predictors or biomarkers to identify subjects at  
17 a high risk of CHD, especially among the hyperuricemia patients, who are deemed a high risk group of  
18 CHD. A wide array of studies indicated that inflammation was involved in the pathogenesis of CHD.<sup>21</sup>  
19 <sup>22</sup> C-reactive protein (CRP), one of the acute phase respondents, is commonly used in clinical practice to  
20 reflect chronic inflammation as an inexpensive measurement.<sup>23</sup> Several epidemiological studies were  
21 undertaken to clarify the relationship between CRP and CHD, but no agreement has been reached.<sup>24-26</sup>  
22 To the best of the authors' knowledge, there has been no study yet examining the association between

1  
2  
3  
4 1 hs-CRP and the CHD risk in hyperuricemia patients. Meaningful outcomes in this respect would not only  
5  
6  
7 2 have important implications in understanding the pathophysiological mechanisms of CHD in  
8  
9  
10 3 hyperuricemia patients, but also contribute to the development of a simple and inexpensive method to  
11  
12 4 predict the future CHD risk of this population.  
13  
14  
15  
16

17 6 To fill this knowledge gap, the present cross-sectional study was carried out to clarify the correlation  
18  
19  
20 7 between hs-CRP and the 10-year estimated CHD risk measured by the Framingham risk score (FRS) in  
21  
22  
23 8 the middle-aged and elderly population with hyperuricemia, with adjustment of conventional  
24  
25 9 cardiovascular risk factors.  
26  
27  
28  
29

## 30 11 **Materials and Methods**

### 31 12 **Study population**

32  
33  
34  
35  
36 13 The participants of the present cross-sectional study were chosen from a pool of subjects who were  
37  
38  
39 14 undergoing routine medical examinations at the Department of Health Examination Center Xiangya  
40  
41  
42 15 Hospital, Central South University in Changsha, Hunan Province of China. The detailed methodology  
43  
44 16 has been described in some earlier studies.<sup>27-32</sup> Briefly, all the qualified participants must be 40 years old  
45  
46  
47 17 or above and undergoing measurements of serum uric acid, hs-CRP, fasting plasma glucose  
48  
49  
50 18 concentration, total cholesterol, high-density lipoprotein (HDL-cholesterol) and creatinine during the  
51  
52  
53 19 specified period. In addition, the subjects should be diagnosed with hyperuricemia (i.e., the uric acid  $\geq$   
54  
55 20 416  $\mu\text{mol/L}$  for male and  $\geq 360 \mu\text{mol/L}$  for female), with availability of demographic and clinical data  
56  
57  
58 21 including age, gender, body mass index (BMI) ( $\text{weight}/\text{height}^2$ ), smoking status, alcohol drinking status,  
59  
60 22 activity level, medication status, etc. Initially, a total of 5994 subjects were included based on the age

1 requirement and availability of blood biochemical assessments (serum uric acid and hs-CRP  
2 measurement) during the period of October 2013 to December 2015. Then, 3420 subjects were  
3 disqualified: 30 were lack of basic health characteristics such as blood pressure and BMI; and 3390 were  
4 lack of information of health-related habits. Of the remaining 2574 subjects, only 517 were diagnosed  
5 with hyperuricemia and were finally enrolled in the present study. The study protocol had been reviewed  
6 and approved by the local Ethics and Research Committee and the written informed consent had been  
7 obtained from all participants prior to execution.

### 9 **Blood biochemistry**

10 All blood samples were drawn from the antecubital vein using vacuum tubes after an overnight fast of  
11  $\geq 12$  hours, and were kept at 4°C until analysis. The hs-CRP was detected by the Latex turbidity method.  
12 The fasting plasma glucose concentration was measured using the glucose oxidase enzyme method. The  
13 uric acid, total cholesterol, HDL-cholesterol and creatinine were all detected using a Beckman Coulter  
14 AU 5800 (Beckman Coulter Inc., Brea, CA, USA). The low concentrations (2.5 mmol/L for glucose and  
15 118  $\mu\text{mol/L}$  for uric acid) and high concentrations (6.7 mmol/L for glucose and 472  $\mu\text{mol/L}$  for uric acid)  
16 of standard human samples were used respectively to evaluate the intra- and inter-assay coefficients of  
17 variation. The intra-assay coefficients of variation were 0.98% (2.5 mmol/L) and 1.72% (6.7 mmol/L)  
18 for glucose, 1.39% (118  $\mu\text{mol/L}$ ) and 0.41% (472  $\mu\text{mol/L}$ ) for uric acid. The inter-assay coefficients of  
19 variation were 2.45% (2.5 mmol/L) and 1.46% (6.7 mmol/L) for glucose, 1.40% (118  $\mu\text{mol/L}$ ) and 1.23%  
20 (472  $\mu\text{mol/L}$ ) for uric acid. A subject was diagnosed with diabetes mellitus if his/her fasting plasma  
21 glucose level  $\geq 7.0$  mmol/L or if he/she was currently receiving medication for blood glucose control.

## 1 **Assessment of other exposures**

2 The BMI was calculated as the weight (kg) divided by the square of the height (m). The blood pressure  
3 was detected at the upper arm using an electronic sphygmomanometer after a rest of at least 10 min.  
4 Then, the status of physical activity, including the average frequency (never, one to two times per week,  
5 three to four times per week, five times and above per week) and the average duration of physical activity  
6 (within half an hour, half an hour to one hour, one to two hours, more than two hours) was collected from  
7 each subject. Lastly, the smoking and alcohol drinking status, as well as the medication conditions of the  
8 subjects were inquired.

## 10 **Assessment of 10-year CHD risk**

11 The risk level of developing CHD was measured by the FRS according to The Adult Treatment Panel III  
12 (ATP III) charts,<sup>33</sup> and the FRS was calculated based on 7 risk factors, which are age, gender, smoking,  
13 systolic blood pressure, use of antihypertensive medication, total cholesterol and HDL cholesterol,  
14 respectively. The specific risk scoring process is as follows: 1) calculate the number of points for each  
15 risk factor; 2) sum up the points of each risk factor to obtain the total risk score; 3) generate the estimated  
16 10-year CHD risk for each patient. The subjects with the 10-year risk above 10% were classified into the  
17 high 10-year CHD risk group.

## 19 **Statistical analysis**

20 For statistical analysis, the continuous variables with a normal distribution were presented as mean  $\pm$   
21 standard deviation, and the category variables were described by frequency and percentage. The  
22 participants were classified into five categories based on the quintile distribution of hs-CRP, namely  $\leq$



1 0.50, 0.51-0.90, 0.91-1.63, 1.63-3.04, and  $\geq 3.05$  mg/L. Baseline characteristics were presented  
2 according to quintiles of hs-CRP, and their trend associations were assessed using a linear regression  
3 analysis for continuous variables or a logistic regression for category variables, with the median value of  
4 hs-CRP in each category assigned to the corresponding category. The association between hs-CRP and  
5 the CHD risk has been described as the odds ratio and 95% confidence intervals, which were calculated  
6 for each quintile of hs-CRP; the lowest quintile was regarded as the reference category. Then, the factors  
7 of BMI, educational background, alcohol drinking status, activity level, serum creatinine and diabetes  
8 that might affect both hs-CRP and the outcomes of interest were included in these models as adjusters.  
9 The trend for relatively high CHD risk according to quartile of hs-CRP was analyzed using the linear  
10 regression model. All data analyses were performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA),  
11 and the level for statistical significance was set as the p-value equal to 0.05. All tests were two tailed.

### 13 **Patient and public involvement**

14 Patients and the public were not involved in setting the research question or the outcome measures, nor  
15 were they involved in the design or implementation of the study. There were no plans to disseminate the  
16 results of the research to study participants.

### 18 **Results**

19 A total of 517 hyperuricemia patients (438 males and 79 females) aged from 40 to 85 years old were  
20 included in the present study. There were 193 (37.3%) patients were defined with relatively high 10-year  
21 CHD risk. The basic characteristics of study population based on the quintiles of hs-CRP were showed  
22 in Table 1. Hyperuricemia patients in the highest level group of hs-CRP were more likely to have a higher

1  
2  
3  
4 1 BMI, higher systolic and diastolic blood pressure, and lower activity level than were those in the lowest  
5  
6  
7 2 level group (P for trend < 0.05 for all).  
8  
9  
10 3

11  
12 4 The results of the associations between hs-CRP and relatively high 10-year CHD risk ( $\geq 10\%$ ) were  
13  
14 5 shown in Table 2. According to the crude OR values, a significant higher prevalence of relatively high  
15  
16  
17 6 CHD risk was observed in the highest quintile (OR=2.12, 95%CI 1.18-3.80, P=0.012) of hs-CRP when  
18  
19  
20 7 comparing with the lowest quintile, and P for trend was 0.057. After adjustment for BMI, educational  
21  
22 8 background, alcohol drinking status, activity level, serum creatinine and diabetes, a positive association  
23  
24  
25 9 between hs-CRP level and relatively high 10-year CHD risk was also observed; the multivariable OR  
26  
27  
28 10 based on a comparison of the highest and the lowest quintile of hs-CRP was 2.10 (95% CI, 1.15-3.84;  
29  
30 11 P=0.016), and P for trend was 0.068.  
31  
32  
33 12

### 34 35 13 **Discussion**

36  
37  
38 14 The present cross-sectional study revealed a borderline positive association between hs-CRP and the  
39  
40  
41 15 high 10-year risk of CHD in the middle-aged and elderly population with hyperuricemia. This correlation  
42  
43  
44 16 didn't changed significantly with adjustment of several potential confounding factors such as BMI,  
45  
46  
47 17 educational background, alcohol drinking status, activity level, serum creatinine and diabetes. These  
48  
49 18 findings suggested that hs-CRP could serve as a marker for the risk of CHD in hyperuricemia patients.  
50  
51  
52 19

53  
54 20 The relationship between CRP and CHD has aroused intensive arguments. Some earlier studies  
55  
56  
57 21 demonstrated that a high level of CRP concentration was positively associated with CHD, and that CRP  
58  
59 22 was predictive of CHD.<sup>34-37</sup> For example, in two nested case-control studies — the Nurses' Health Study

1 and the Health Professionals Follow-up Study — Jennifer et al. found that a high level of CRP was  
2 associated with an increased risk of CHD among participants with no history of cardiovascular disease  
3 and that the level of CRP could be considered as a predictor of CHD.<sup>38</sup> In the Cardiovascular Health  
4 Study, elevated CRP was found to be associated with an increased 10-year risk of CHD, regardless of  
5 the presence of conventional risk factors.<sup>39</sup> Besides, a cross-sectional study conducted in Japan  
6 demonstrated that hs-CRP was associated with the estimated risk level of CHD in the middle-aged men.<sup>40</sup>  
7 However, controversy remains with respect to the association of CRP with CHD, and the predictive value  
8 of CRP. According to the data obtained from the MONICA Optional Haemostasis Study, no significant  
9 correlation was observed between the CHD event rate and the plasma CRP in the European populations.<sup>41</sup>  
10 Similarly, it was shown that the CRP level was not significantly associated with CHD with adjustment  
11 of conventional risk factors in the post-menopausal women.<sup>42</sup> Meanwhile, the findings from the 1999–  
12 2004 NHANES suggested that hs-CRP was not associated with the CHD mortality.<sup>43</sup> The present study  
13 further revealed that CRP was positively associated with CHD in patients with hyperuricemia.

14  
15 Previous *in vivo* and *in vitro* studies have suggested that CRP modulated many factors involved in  
16 atherosclerosis, which might explain the positive association between the CRP level and CHD. CRP  
17 could reduce the endothelial nitric oxide synthase both at the protein and mRNA levels and promote the  
18 production of inducible nitric oxide synthase and endothelin-1 in endothelial cells.<sup>38 39</sup> Besides, it was  
19 reported that the adhesion and internalization of white blood cells onto the arterial wall were improved  
20 by CRP by inducing the expression of vascular cell adhesion molecule-1, intercellular adhesion  
21 molecule-1, E-selectin, and monocyte chemoattractant protein-1.<sup>44 45</sup> Moreover, CRP could also induce  
22 the monocyte chemotaxis and differentiation,<sup>46 47</sup> and facilitate the uptake of oxidized low-density

1 lipoprotein through macrophages and monocyte-platelets aggregation.<sup>48 49</sup> Further evidence supported  
2 CRP as a participant in later stages of atherosclerosis with the expression of matrix metalloproteinases  
3 and collagenase activity in human monocyte-macrophages.<sup>50 51</sup>

4  
5 The present study clarified that high hs-CRP was correlated with a high CHD risk in the middle-  
6 aged and elderly population with hyperuricemia, while several previous study have shown that CRP was  
7 not significantly associated with CHD in general population or other population.<sup>24 42</sup> It is suggested that  
8 hyperuricemia interacts synergistically with high hs-CRP subjects, and may subsequently enhance the  
9 risk of CHD predictor value of hs-CRP. This has implications for clinicians to predict the CHD risk in  
10 hyperuricemia patients based on hs-CRP, an easily measured clinical marker, and thereby providing  
11 preventive measures accordingly. Meanwhile, it also prompts that uric acid may interact with other risk  
12 factors during the development and progression of CHD, but such conclusion needs to be validated by  
13 further study.

14  
15 Several strengths and shortcomings of this study are worth mentioning. First, this is the first study  
16 exploring the association between hs-CRP and the CHD risk in patients with hyperuricemia in the  
17 middle-aged and elderly population. Second, multivariable models were used to analyze the  
18 aforementioned relationship by adjusting a considerable number of potential confounding factors, such  
19 as BMI, serum creatinine and diabetes. As for the limitation, no causal relationship can be established in  
20 the present study due to the nature of cross-sectional design. However, the primary objective of this study  
21 was to examine the association between CRP and the CHD risk rather than to prove that CRP could  
22 increase the incidence of CHD. As CRP was deemed to be correlated with the CHD risk score, it can be

1 used to reflect this complicated index in clinical practice. Subsequently, other more complicated indexes  
2 such as the Framingham risk score could be used to examine the CHD risk. Therefore, it can be  
3 speculated that CRP may have the potential to be an easily accessible screening method in the future  
4 after further studies' confirmation.

## 6 **Conclusion**

7 This study showed that there was a borderline association between high serum hs-CRP level and high  
8 CHD risk in middle-aged and elderly population with hyperuricemia, which suggested that serum hs-  
9 CRP, a routine index in clinical practice, may be used to predict CHD risk in hyperuricemia patients.

1  
2  
3  
4 1 **Contributors** MX, DX, HL and XD were responsible for the conception and design of the study. KL,  
5  
6 2 BZ and ZY contributed to the statistical analyses. MX, DX, HL, XD, YY and YZ contributed to the data  
7  
8  
9 3 collection and interpretation. MX, DX, HL and XD drafted the manuscript. HL, XD and ZY contributed  
10  
11  
12 4 to the revision of the manuscript. All authors read and approved the final manuscript.

13  
14 5 **Funding** This work was supported by the National Natural Science Foundation of China (81772413,  
15  
16  
17 6 81702207, 81702206), the Young Investigator Grant of Xiangya Hospital, Central South University  
18  
19  
20 7 (2017Q10), and the Postgraduate Independent Exploration and Innovation Project of Central South  
21  
22  
23 8 University (2018zzts256).

24  
25 9 **Competing interests** None declared.

26  
27  
28 10 **Patient consent** Not required.

29  
30  
31 11 **Ethics approval** This study was approved by the ethics committee of Xiangya Hospital, Central South  
32  
33 12 University.

34  
35  
36 13 **Data sharing statement:** No additional data available.

37  
38  
39 14

40  
41  
42 15

43  
44  
45 16

46  
47  
48 17

49  
50  
51 18

52  
53  
54 19

55  
56  
57 20

58  
59  
60 21

22

1  
2  
3  
4 **1 References:**  
5

- 6  
7 2 1. Hak AE, Choi HK. Lifestyle and gout. *Current Opinion in Rheumatology* 2008;20:179-86.  
8  
9 3 2. Zhai FY, He YN, Ma GS, et al. [Study on the current status and trend of food consumption among  
10 Chinese population]. *Chinese Journal of Epidemiology* 2005;26:485.  
11  
12 4  
13  
14 5 3. Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to  
15 2014: A Systematic Review and Meta-Analysis. *Biomed Research International* 2015;2015:762820.  
16  
17 6  
18  
19 7 4. Onat A, Uyarel H, Hergenç G, et al. Serum Uric Acid Is a Determinant of Metabolic Syndrome in a  
20 Population-Based Study. *American Journal of Hypertension* 2006;19:1055-62.  
21  
22 8  
23  
24 9 5. Oda E. Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health  
25 screening population. *Heart & Vessels* 2014;29:496-503.  
26  
27 10  
28  
29 11 6. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing  
30 ESRD in a screened cohort. *American Journal of Kidney Diseases* 2004;44:642-50.  
31  
32 12  
33  
34 13 7. Chang HY, Tung CW, Lee PH, et al. Hyperuricemia as an independent risk factor of chronic kidney  
35 disease in middle-aged and elderly population. *American Journal of the Medical Sciences* 2010;339:509-  
36 15.  
37  
38 14  
39  
40 15  
41  
42 16 8. Li M, Hou W, Zhang X, et al. Hyperuricemia and risk of stroke: a systematic review and meta-  
43 analysis of prospective studies. *Atherosclerosis* 2014;232:265-70.  
44  
45 17  
46  
47 18 9. Lai X, Yang L, Légaré S, et al. Dose-response relationship between serum uric acid levels and risk  
48 of incident coronary heart disease in the Dongfeng-Tongji Cohort. *International Journal of Cardiology*  
49 2016;224:299-304.  
50  
51 19  
52  
53 20 10. Braga F, Pasqualetti S, Ferraro S, et al. Hyperuricemia as risk factor for coronary heart disease  
54 incidence and mortality in the general population: a systematic review and meta-analysis. *Clinical*  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 *Chemistry & Laboratory Medicine* 2016;54:7-15.
- 5  
6 2 11. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: A systematic review  
7  
8  
9 3 and meta - analysis. *Arthritis Care & Research* 2010;62:170-80.
- 10  
11 4 12. Coutinho TDA, Turner ST, Peyser PA, et al. Associations of Serum Uric Acid With Markers of  
12  
13  
14 5 Inflammation, Metabolic Syndrome, and Subclinical Coronary Atherosclerosis. *American Journal of*  
15  
16  
17 6 *Hypertension* 2007;20:83-9.
- 18  
19  
20 7 13. Perlstein TS, Gumieniak O, Williams GH, et al. Uric Acid and the Development of Hypertension  
21  
22  
23 8 The Normative Aging Study. *Hypertension* 2006;48:1031-36.
- 24  
25 9 14. Li Q, Yang Z, Lu B, et al. Serum uric acid level and its association with metabolic syndrome and  
26  
27  
28 10 carotid atherosclerosis in patients with type 2 diabetes. *Cardiovascular Diabetology* 2011;10:1-7.
- 29  
30  
31 11 15. Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations  
32  
33  
34 12 predict subsequent weight gain and blood pressure elevation. *Hypertension* 2003;42:474-80.
- 35  
36 13 16. Nakanishi N, Okamoto M, Yoshida H, et al. Serum Uric Acid and Risk for Development of  
37  
38  
39 14 Hypertension and Impaired Fasting Glucose or Type II Diabetes in Japanese Male Office Workers.  
40  
41  
42 15 *European Journal of Epidemiology* 2003;18:523-30.
- 43  
44 16 17. Dehghan A, Hoek MV, Sijbrands EJG, et al. High Serum Uric Acid as a Novel Risk Factor for Type  
45  
46  
47 17 2 Diabetes. *Diabetes Care* 2008;31:361-2.
- 48  
49 18 18. Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components  
50  
51  
52 19 of the insulin resistance syndrome in young black and white adults: the CARDIA study. *Coronary Artery*  
53  
54  
55 20 *Risk Development in Young Adults. Annals of Epidemiology* 1998;8:250-61.
- 56  
57 21 19. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. *Kidney*  
58  
59  
60 22 *International* 2005;67:1739-42.



- 1  
2  
3  
4 1 20. Lloyd-Jones. Heart Disease and Stroke Statistics-2009 Update: A Report From the American Heart  
5  
6  
7 2 Association Statistics Committee and Stroke Statistics Subcommittee (vol 119, pg e21, 2009).  
8  
9 3 *Circulation* 2011;124:E424.  
10  
11  
12 4 21. Libby P, Sukhova G, Lee RT, et al. Cytokines regulate vascular functions related to stability of the  
13  
14 5 atherosclerotic plaque. *J Cardiovasc Pharmacol* 1995;25 Suppl 2:S9.  
16  
17 6 22. Ross R. Atherosclerosis-inflammatory disease. *N Engl J Med* 1999;340.  
18  
19  
20 7 23. Savve VD, Ushakov GS. C-reactive protein, a sensitive marker for inflammation, predicts future risk  
21  
22 8 of coronary heart disease in initially healthy middle-aged men: Koenig W, Sund M, Frohlich M, et al:  
23  
24 9 *Circulation* 99: 237 - 242, 1999. *Zhurnal Mikrobiologii Epidemiologii I Immunobiologii* 1962;33:15-20.  
26  
27  
28 10 24. Yarnell J, Mccrum E, Rumley A, et al. Association of European population levels of thrombotic and  
29  
30 11 inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study†.  
31  
32 12 *European Heart Journal* 2005;26:332-42.  
34  
35  
36 13 25. Otsuka T, Kawada T, Katsumata M, et al. High-sensitivity C-reactive protein is associated with the  
37  
38 14 risk of coronary heart disease as estimated by the Framingham Risk Score in middle-aged Japanese men.  
39  
40 15 *International Journal of Cardiology* 2008;129:245-50.  
42  
43  
44 16 26. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of  
45  
46 17 inflammation in the prediction of coronary heart disease. *Acc Current Journal Review* 2004;13:27-8.  
47  
48  
49 18 27. Zeng C, Li H, Wei J, et al. Association between Dietary Magnesium Intake and Radiographic Knee  
50  
51 19 Osteoarthritis. *Plos One* 2015;10: e0127666.  
52  
53  
54 20 28. Zeng C, Wei J, Li H, et al. Relationship between Serum Magnesium Concentration and Radiographic  
55  
56 21 Knee Osteoarthritis. *Journal of Rheumatology* 2015;42:1231-6.  
57  
58  
59 22 29. Zeng C, Wang YL, Wei J, et al. Association between low serum magnesium concentration and  
60

- 1  
2  
3  
4 1 hyperuricemia. *Magnesium Research Official Organ of the International Society for the Development of*  
5  
6  
7 2 *Research on Magnesium* 2015;28:56.
- 8  
9 3 30. Xie DX, Xiong YL, Zeng C, et al. Association between low dietary zinc and hyperuricaemia in  
10  
11  
12 4 middle-aged and older males in China: a cross-sectional study. *BMJ Open* 2015;5:e008637.
- 13  
14 5 31. Xiong Y, Wei J, Zeng C, et al. Association between dietary iron intake and bone mineral density: A  
15  
16  
17 6 cross-sectional study in Chinese population. *Nutrition & Dietetics* 2016;73:433-40.
- 18  
19  
20 7 32. Li H, Zeng C, Wei J, et al. Associations between dietary antioxidants intake and radiographic knee  
21  
22  
23 8 osteoarthritis. *Clinical Rheumatology* 2016;35:1585-92.
- 24  
25 9 33. Program NCE. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel  
26  
27  
28 10 on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel  
29  
30  
31 11 III) final report. *Circulation* 2002;106:3143-421.
- 32  
33 12 34. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary  
34  
35  
36 13 heart disease in older men and women: the cardiovascular health study. *Circulation* 2005;112:25-31.
- 37  
38  
39 14 35. Straczek C, Ducimetiere P, Barbergergateau P, et al. Higher level of systemic C-reactive protein is  
40  
41  
42 15 independently predictive of coronary heart disease in older community-dwelling adults: the three-city  
43  
44 16 study. *Journal of the American Geriatrics Society* 2010;58:129-35.
- 45  
46 17 36. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of  
47  
48  
49 18 inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004;350:1387-97.
- 50  
51  
52 19 37. Kaptoge S, Angelantonio ED, Lowe G, et al. C-reactive protein concentration and risk of coronary  
53  
54  
55 20 heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* 2010;375:132-40.
- 56  
57 21 38. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration That C-Reactive Protein Decreases eNOS  
58  
59  
60 22 Expression and Bioactivity in Human Aortic Endothelial Cells. *Circulation* 2002;106:1439-41.

- 1  
2  
3  
4 1 39. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate  
5  
6 2 the proatherogenic effects of C-reactive protein. *Circulation* 2002;105:1890.  
7  
8  
9 3 40. Otsuka T, Kawada T, Katsumata M, et al. High-sensitivity C-reactive protein is associated with the  
10  
11 4 risk of coronary heart disease as estimated by the Framingham Risk Score in middle-aged Japanese men.  
12  
13 5 *International Journal of Cardiology* 2008;129:245.  
14  
15  
16 6 41. Yarnell J, Mccrum E, Rumley A, et al. Association of European population levels of thrombotic and  
17  
18 7 inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study.  
19  
20 8 *European Heart Journal* 2005;26:332-42.  
21  
22  
23 9 42. Kim HC, Greenland PRossouw JE, Manson JE, et al. Multimarker prediction of coronary heart  
24  
25 10 disease risk: the Women's Health Initiative. *Journal of the American College of Cardiology*  
26  
27 11 2010;55:2080-91.  
28  
29  
30 12 43. Veeranna V, Zalawadiya SK, Panaich S, et al. Comparative analysis of red cell distribution width  
31  
32 13 and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic  
33  
34 14 population: findings from the 1999-2004 NHANES. *International Journal of Cardiology*  
35  
36 15 2013;168:5156-61.  
37  
38  
39 16 44. Pasceri V, Willerson JT, Yeh ET, et al. Direct proinflammatory effect of C-reactive protein on human  
40  
41 17 endothelial cells. *Circulation* 2000;102:2165-8.  
42  
43  
44 18 45. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte  
45  
46 19 chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. *Circulation*  
47  
48 20 2001;103:2531-4.  
49  
50  
51 21 46. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive  
52  
53 22 protein receptor-dependent monocyte recruitment in atherogenesis. *Arteriosclerosis Thrombosis &*

- 1  
2  
3  
4 1 *Vascular Biology* 2000;20:2094.  
5  
6  
7 2 47. Zhang R, Becnel L, Li M, et al. C-reactive protein impairs human CD14+ monocyte-derived dendritic  
8  
9 3 cell differentiation, maturation and function. *European Journal of Immunology* 2006;36:2993-3006.  
10  
11  
12 4 48. Chang MK, Binder CJ, Torzewski M, et al. C-reactive protein binds to both oxidized LDL and  
13  
14 5 apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids.  
15  
16  
17 6 *Proceedings of the National Academy of Sciences of the United States of America* 2002;99:13043-48.  
18  
19  
20 7 49. Zwaka TP, Hombach V, Torzewski J, et al. C-reactive protein-mediated low density lipoprotein  
21  
22 8 uptake by macrophages: implications for atherosclerosis. *Circulation* 2001;103:1194-7.  
23  
24  
25 9 50. Williams TN, Zhang CX, Game BA, et al. C-Reactive Protein Stimulates MMP-1 Expression in  
26  
27 10 U937 Histiocytes Through Fc  $\gamma$  RII and Extracellular Signal-Regulated Kinase Pathway: An Implication  
28  
29 11 of CRP Involvement in Plaque Destabilization. *Arterioscler Thromb Vasc Biol* 2004;24:61-6.  
30  
31  
32  
33 12 51. Nabata A, Kuroki M, Ueba H, et al. C-reactive protein induces endothelial cell apoptosis and matrix  
34  
35 13 metalloproteinase-9 production in human mononuclear cells: Implications for the destabilization of  
36  
37 14 atherosclerotic plaque. *Atherosclerosis* 2008;196:129.  
38  
39  
40  
41 15  
42  
43 16  
44  
45 17  
46  
47 18  
48  
49 19  
50 20  
51  
52 21  
53  
54 22  
55  
56 23  
57  
58 24  
59 25  
60

1 Table 1 Basic characteristics of study population based on the quintiles of hs-CRP level (n=517)

Characteristics	Quintiles of hs-CRP (mg/L)					P for trend
	1 (≤0.50)	2 (0.51-0.90)	3 (0.91-1.63)	4 (1.64-3.04)	5 (≥3.05)	
N	108	99	106	100	104	
<b>Demographic characteristics</b>						
Age (years)	50.2 (6.6)	50.2 (5.6)	51.3 (7.3)	51.4 (6.0)	51.5 (7.4)	0.165
Female (%)	13.0	13.1	13.2	19.0	18.3	0.206
Educational background (High school or above, %)	66.7	53.5	75.5	66.0	62.5	0.743
<b>Clinical characteristics</b>						
BMI (kg/m <sup>2</sup> )	25.3 (3.2)	26.0 (2.6)	26.8 (3.1)	26.8 (3.0)	27.0 (3.6)	0.001
Relatively high CHD risk (≥10%, %)	25.0	32.3	40.6	48.0	41.3	0.057
Systolic blood pressure (mmHg)	129.4 (14.3)	132.7 (15.7)	133.6 (15.5)	135.6 (16.9)	136.3 (17.4)	0.873
Diastolic blood pressure (mmHg)	82.1 (11.0)	84.3 (11.5)	85.1 (11.3)	86.3 (11.6)	87.5 (12.2)	0.151
Diabetes (yes, %)	12.0	12.1	11.3	18.0	17.3	0.174
<b>Biochemical characteristics</b>						
Total cholesterol (mg/dl)	202.8 (35.6)	209.1 (37.9)	207.8 (40.9)	211.1 (41.4)	206.7 (49.6)	0.873
HDL cholesterol (mg/dl)	53.2 (13.4)	51.6 (13.5)	51.8 (9.6)	50.7 (12.1)	49.5 (10.6)	0.151
Serum creatinine (μmol/L)	100.5 (32.8)	104.4 (49.7)	98.9 (14.9)	99.5 (34.9)	99.1 (17.6)	0.528
<b>Lifestyle characteristics</b>						
Activity level (h/week)	2.0 (2.5)	1.3 (2.3)	1.8 (2.9)	1.6 (2.7)	1.2 (2.3)	0.047
Smoking (yes, %)	24.1	29.3	34.9	36.0	35.6	0.165
Alcohol drinking (yes, %)	53.7	61.6	63.2	61.0	52.9	0.328

2 Data are mean (standard deviation), unless otherwise indicated; hs-CRP, hypersensitive C-reactive  
3 protein; BMI, body mass index; HDL, high density lipoprotein.

4

1 Table 2 Associations between hs-CRP and relatively high 10-year CHD risk ( $\geq 10\%$ ) in  
 2 hyperuricemia population (n=517)

		Quintiles of hs-CRP (mg/L)					P for trend
		1 ( $\leq 0.50$ )	2 (0.51-0.90)	3 (0.91-1.63)	4 (1.64-3.04)	5 ( $\geq 3.05$ )	
Participants (n)		108	99	106	100	104	
Median hs-CRP (mg/L)		0.34	0.69	1.21	2.11	6.12	
Crude	OR	1.00	1.43	2.05	2.77	2.12	0.057
	(95%CI)	(reference)	(0.78, 2.63)	(1.14, 3.67)	(1.54, 4.98)	(1.18, 3.80)	
	P values	-	0.245	0.016	0.001	0.012	
Multivariable							
adjusted	OR	1.00	1.40	2.05	2.69	2.10	0.068
	(95% CI)	(reference)	(0.75, 2.61)	(1.13, 3.72)	(1.47, 4.89)	(1.15, 3.84)	
	P values	-	0.291	0.019	0.001	0.016	

3 \*Multivariable adjusted model was adjusted for BMI, educational background, alcohol drinking  
 4 status, activity level, serum creatinine and diabetes. hs-CRP, hypersensitive C-reactive protein;  
 5 CHD, coronary heart disease; OR, odds ratio; CI, confidence interval.

6

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4,5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5, 6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5,6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7, 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7, 8
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	7,8

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	5, 6
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	19
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8,9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	19
		(b) Report category boundaries when continuous variables were categorized	20
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	20
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9,10,11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## Association of high-sensitivity C-reactive protein in middle-aged and elderly Chinese people with hyperuricemia and risk of coronary heart disease: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028351.R2
Article Type:	Original research
Date Submitted by the Author:	14-Sep-2019
Complete List of Authors:	Xie, Mingsheng; Xiangya Hospital Central South University, Department of Orthopaedics Xie, Dongxing; Xiangya Hospital, Central South University, Department of Orthopaedics Yang, Ye; Xiangya Hospital Central South University, Department of Orthopaedics Zhang, Yi; Xiangya Hospital, Orthopaedics Li, Kun; Xiangya Hospital Central South University, Department of Orthopaedics Zhou, Bin; Xiangya Hospital Central South University, Department of Orthopaedics Yang, Zidan; Xiangya School of Public Health, Central South University, Department of Epidemiology and Health Statistics Ding, Xiang; Xiangya Hospital Central South University Li, Hui; Xiangya Hospital, Central South University, Department of Orthopaedics
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	high-sensitivity C-reactive protein, hyperuricemia, Coronary heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 1 **Association of high-sensitivity C-reactive protein in middle-aged and elderly Chinese people**  
5  
6 2 **with hyperuricemia and risk of coronary heart disease: a cross-sectional study**  
7  
8  
9

10 3 Mingsheng Xie<sup>1</sup>†, Dongxing Xie<sup>1</sup>†, Ye Yang<sup>1</sup>, Yi Zhang<sup>1</sup>, Kun Li<sup>1</sup>, Bin Zhou<sup>1</sup>, Zidan Yang,<sup>2</sup> Xiang  
11  
12  
13 4 Ding<sup>1</sup>\*, Hui Li<sup>1,3</sup>\*

14  
15  
16  
17  
18 5 <sup>1</sup> Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China;

19  
20 6 <sup>2</sup> Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South  
21  
22  
23 7 University, Changsha, Hunan, China; <sup>3</sup> Hunan Key Laboratory of Joint Degeneration and Injury,  
24  
25  
26 8 Changsha, Hunan, China.

27  
28  
29  
30 9 **Email address:** Mingsheng Xie<sup>1</sup>: Mingsheng-Xie2016@csu.edu.cn; Dongxing Xie:  
31  
32  
33 10 xdx1024@csu.edu.cn; Ye Yang: 411859291@qq.com; Yi Zhang: 57234919@qq.com; Kun Li:  
34  
35  
36 11 332845996@qq.com; Bin Zhou: 673962793@qq.com; Xiang Ding: dingxiang@csu.edu.cn; Hui Li<sup>2</sup>:  
37  
38  
39 12 lihui1988@csu.edu.cn

40  
41  
42  
43 13 **Correspondence to:** Hui Li, MD, PhD, Department of Orthopaedics, Xiangya Hospital, Central South  
44  
45  
46 14 University, #87 Xiangya Road, Changsha, Hunan, China, E-mail: lihui1988@csu.edu.cn; **Xiang**  
47  
48 15 **Ding**, MD, PhD, Department of Orthopaedic, Xiangya Hospital, Central South University, #87  
49  
50  
51 16 Xiangya Road, Changsha, Hunan, 410008, China. E-mail: dingxiang@csu.edu.cn.

52  
53 17  
54  
55 18

56  
57  
58  
59 

---

<sup>1</sup> Mingsheng Xie and Dongxing Xie contributed equally to this article.

60 <sup>2</sup> Hui Li and Xiang Ding contributed equally to this article.

1

2 **Abstract**

3 **OBJECTIVES:** Hyperuricemia patients are at relatively high risk of developing coronary heart disease  
4 (CHD). The purpose of this study was to examine the relationship between high-sensitivity C-reactive  
5 protein (hs-CRP) and CHD risk in a middle-aged and elderly population with hyperuricemia.

6 **DESIGN:** A cross-sectional study.

7 **SETTING AND PARTICIPANTS:** This study was conducted in a health examination center of China.  
8 Participants were diagnosed with hyperuricemia based on uric acid concentrations. Specifically, males  
9 with a uric acid concentration  $\geq 416$   $\mu\text{mol/L}$  were included, as well as females with a concentration  $\geq$   
10 360  $\mu\text{mol/L}$ .

11 **MAIN OUTCOME MEASURES:** 10-year CHD risk for each individual was evaluated using  
12 Framingham risk score based on the Adult Treatment Panel III charts.

13 **RESULTS:** A total of 517 hyperuricemia patients (438 males and 79 females) aged from 40 to 85 years  
14 old were included in the present study. 193 (37.3%) patients were defined with relatively high 10-year  
15 CHD risk. Compared with the lowest quintile, the crude odds ratio (ORs) of relatively high 10-year CHD  
16 risks were 1.43 (95%CI 0.78-2.63, P=0.245), 2.05 (95%CI 1.14-3.67, P=0.016), 2.77 (95%CI 1.54-4.98,  
17 P=0.001), 2.12 (95%CI 1.18-3.80, P=0.012) in the second, third, fourth and fifth quintiles of serum hs-  
18 CRP level, respectively (P for trend = 0.057). The multivariable-adjusted ORs of relatively high 10-year  
19 CHD risk were 1.40 (95%CI 0.75-2.61, P=0.291) in the second, 2.05 (95%CI 1.13-3.72, P=0.019) in the  
20 third, 2.69 (95%CI 1.47-4.89, P=0.001) in the fourth, and 2.10 (95%CI 1.15-3.84, P=0.016) in the fifth  
21 quintile of serum hs-CRP level when compared with the lowest quintile (P for trend = 0.068).

22 **CONCLUSION:** This study showed that ORs of relatively high 10-year CHD risk were raised in

1 hyperuricemia patients with higher serum hs-CRP level, however, there was a not significant but  
2 borderline trend association and that more research is needed.

3 **Key words:** hyperuricemia, high-sensitivity C-reactive protein, coronary heart disease

#### 6 **Strengths and limitations of this study**

7 1. This is the first study exploring the association between hs-CRP and the CHD risk in patients with  
8 hyperuricemia in a middle-aged and elderly population with hyperuricemia.

9 2. The relationship of hs-CRP and the CHD risk was analyzed by multivariable models.

10 3. As result of the nature of cross-sectional design, the causal relationship cannot be established in the  
11 present study.

12 4. Though FRS has been used to assess the risk of cardiovascular events in Chinese population, it is  
13 noteworthy that FRS was originally constructed for the US population using a US population data.

## 1 **Background**

2 Serum uric acid is the catabolic end-product of purine metabolism via the catalysis of xanthine oxidase.  
3 With the rapid economic development, the dietary habits of Chinese people have changed greatly towards  
4 an increasingly heavier intake of meat, dairy products and other purine enriched foods, which has led to  
5 a higher prevalence of hyperuricemia and gout susceptibly.<sup>1 2</sup> A systematic review and meta-analysis  
6 involving 44 studies showed that the pooled prevalence of hyperuricemia was 13.3% in mainland China  
7 from 2000 to 2014.<sup>3</sup> Some previous studies reported that an increase in serum uric acid was incriminated  
8 in the pathogenesis of metabolic syndrome,<sup>4 5</sup> chronic kidney disease,<sup>6 7</sup> stroke,<sup>8</sup> and coronary heart  
9 disease (CHD).<sup>9 10</sup>

11 Over the past several decades, relevant studies have shown that an increased serum uric acid was  
12 significantly associated with CHD, independent of conventional CHD risk factors.<sup>9-12</sup> Besides, it was  
13 also demonstrated that increased uric acid was correlated with hypertension, diabetes mellitus, metabolic  
14 syndrome, hypertriglyceridemia and endothelial dysfunction.<sup>6 13-19</sup> All of which could lead to an increased  
15 risk of CHD. With the trend of population aging, CHD has become one of the most common causes of  
16 death.<sup>20</sup> Therefore, it is urgent to seek effective predictors or biomarkers to identify subjects at a high  
17 risk of CHD, especially among the hyperuricemia patients, who are deemed a high risk group of CHD.  
18 A wide array of studies indicated that inflammation was involved in the pathogenesis of CHD.<sup>21 22</sup> C-  
19 reactive protein (CRP), one of the acute phase respondents, is commonly used in clinical practice to  
20 reflect chronic inflammation as an inexpensive measurement.<sup>23</sup> Several epidemiological studies were  
21 undertaken to clarify the relationship between CRP and CHD, but no agreement has been reached.<sup>24-26</sup>  
22 To the best of the authors' knowledge, there has been no study yet examining the association between

1  
2  
3  
4 1 hs-CRP and the CHD risk in hyperuricemia patients. Meaningful outcomes in this respect would not only  
5  
6  
7 2 have important implications in understanding the pathophysiological mechanisms of CHD in  
8  
9  
10 3 hyperuricemia patients, but also contribute to the development of a simple and inexpensive method to  
11  
12 4 predict the future CHD risk of this population.  
13  
14  
15  
16

17 6 To fill this knowledge gap, the present cross-sectional study was carried out to clarify the correlation  
18  
19  
20 7 between hs-CRP and the 10-year estimated CHD risk measured by the Framingham risk score (FRS) in  
21  
22 8 the middle-aged and elderly population with hyperuricemia, with adjustment of conventional  
23  
24  
25 9 cardiovascular risk factors.  
26  
27  
28  
29

## 30 11 **Materials and Methods**

### 31 12 **Study population**

32  
33  
34  
35 13 The participants of the present cross-sectional study were chosen from a pool of subjects who were  
36  
37  
38 14 undergoing routine medical examinations at the Department of Health Examination Center Xiangya  
39  
40  
41 15 Hospital, Central South University in Changsha, Hunan Province of China. The detailed methodology  
42  
43  
44 16 has been described in some earlier studies.<sup>27-32</sup> Briefly, all the qualified participants must be 40 years old  
45  
46 17 or above and undergoing measurements of serum uric acid, hs-CRP, fasting plasma glucose  
47  
48  
49 18 concentration, total cholesterol, high-density lipoprotein (HDL-cholesterol) and creatinine during the  
50  
51  
52 19 specified period. In addition, the subjects should be diagnosed with hyperuricemia (i.e., the uric acid  $\geq$   
53  
54 20 416  $\mu\text{mol/L}$  for male and  $\geq$  360  $\mu\text{mol/L}$  for female), with availability of demographic and clinical data  
55  
56  
57 21 including age, gender, body mass index (BMI) ( $\text{weight}/\text{height}^2$ ), smoking status, alcohol drinking status,  
58  
59  
60 22 activity level, medication status, etc. Initially, a total of 5994 subjects were included based on the age

1 requirement and availability of blood biochemical assessments (serum uric acid and hs-CRP  
2 measurement) during the period of October 2013 to December 2015. Then, 3420 subjects were  
3 disqualified: 30 were lack of basic health characteristics such as blood pressure and BMI; and 3390 were  
4 lack of information of health-related habits. Of the remaining 2574 subjects, only 517 were diagnosed  
5 with hyperuricemia and were finally enrolled in the present study. The study protocol had been reviewed  
6 and approved by the local Ethics and Research Committee and the written informed consent had been  
7 obtained from all participants prior to execution.

### 9 **Blood biochemistry**

10 All blood samples were drawn from the antecubital vein using vacuum tubes after an overnight fast of  
11  $\geq 12$  hours, and were kept at 4°C until analysis. The hs-CRP was detected by the Latex turbidity method.  
12 The fasting plasma glucose concentration was measured using the glucose oxidase enzyme method. The  
13 uric acid, total cholesterol, HDL-cholesterol and creatinine were all detected using a Beckman Coulter  
14 AU 5800 (Beckman Coulter Inc., Brea, CA, USA). The low concentrations (2.5 mmol/L for glucose and  
15 118  $\mu\text{mol/L}$  for uric acid) and high concentrations (6.7 mmol/L for glucose and 472  $\mu\text{mol/L}$  for uric acid)  
16 of standard human samples were used respectively to evaluate the intra- and inter-assay coefficients of  
17 variation. The intra-assay coefficients of variation were 0.98% (2.5 mmol/L) and 1.72% (6.7 mmol/L)  
18 for glucose, 1.39% (118  $\mu\text{mol/L}$ ) and 0.41% (472  $\mu\text{mol/L}$ ) for uric acid. The inter-assay coefficients of  
19 variation were 2.45% (2.5 mmol/L) and 1.46% (6.7 mmol/L) for glucose, 1.40% (118  $\mu\text{mol/L}$ ) and 1.23%  
20 (472  $\mu\text{mol/L}$ ) for uric acid. A subject was diagnosed with diabetes mellitus if his/her fasting plasma  
21 glucose level  $\geq 7.0$  mmol/L or if he/she was currently receiving medication for blood glucose control.

## 1 **Assessment of other exposures**

2 The BMI was calculated as the weight (kg) divided by the square of the height (m). The blood pressure  
3 was detected at the upper arm using an electronic sphygmomanometer after a rest of at least 10 min.  
4 Then, the status of physical activity, including the average frequency (never, one to two times per week,  
5 three to four times per week, five times and above per week) and the average duration of physical activity  
6 (within half an hour, half an hour to one hour, one to two hours, more than two hours) was collected from  
7 each subject. Lastly, the smoking and alcohol drinking status, as well as the medication conditions of the  
8 subjects were inquired.

## 10 **Assessment of 10-year CHD risk**

11 The risk level of developing CHD was measured by the FRS according to The Adult Treatment Panel III  
12 (ATP III) charts,<sup>33</sup> and the FRS was calculated based on 7 risk factors, which are age, gender, smoking,  
13 systolic blood pressure, use of antihypertensive medication, total cholesterol and HDL cholesterol,  
14 respectively. The specific risk scoring process is as follows: 1) calculate the number of points for each  
15 risk factor; 2) sum up the points of each risk factor to obtain the total risk score; 3) generate the estimated  
16 10-year CHD risk for each patient. The subjects with the 10-year risk above 10% were classified into the  
17 high 10-year CHD risk group.

## 19 **Statistical analysis**

20 For statistical analysis, the continuous variables with a normal distribution were presented as mean  $\pm$   
21 standard deviation, and the category variables were described by frequency and percentage. The  
22 participants were classified into five categories based on the quintile distribution of hs-CRP, namely  $\leq$



1 0.50, 0.51-0.90, 0.91-1.63, 1.63-3.04, and  $\geq 3.05$  mg/L. Baseline characteristics were presented  
2 according to quintiles of hs-CRP, and their trend associations were assessed using a linear regression  
3 analysis for continuous variables or a logistic regression for category variables, with the median value of  
4 hs-CRP in each category assigned to the corresponding category. The association between hs-CRP and  
5 the CHD risk has been described as the odds ratio and 95% confidence intervals, which were calculated  
6 for each quintile of hs-CRP; the lowest quintile was regarded as the reference category. Then, the factors  
7 of BMI, educational background, alcohol drinking status, activity level, serum creatinine and diabetes  
8 that might affect both hs-CRP and the outcomes of interest were included in these models as adjusters.  
9 The trend for relatively high CHD risk according to quartile of hs-CRP was analyzed using the linear  
10 regression model. All data analyses were performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA),  
11 and the level for statistical significance was set as the p-value equal to 0.05. All tests were two tailed.

### 13 **Patient and public involvement**

14 Patients and the public were not involved in setting the research question or the outcome measures, nor  
15 were they involved in the design or implementation of the study. There were no plans to disseminate the  
16 results of the research to study participants.

### 18 **Results**

19 A total of 517 hyperuricemia patients (438 males and 79 females) aged from 40 to 85 years old were  
20 included in the present study. There were 193 (37.3%) patients were defined with relatively high 10-year  
21 CHD risk. The basic characteristics of study population based on the quintiles of hs-CRP were showed  
22 in Table 1. Hyperuricemia patients in the highest level group of hs-CRP were more likely to have a higher

1 BMI and lower activity level than were those in the lowest level group (P for trend < 0.05 for all).

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 The results of the associations between hs-CRP and relatively high 10-year CHD risk ( $\geq 10\%$ ) were  
2  
3 shown in Table 2. According to the crude OR values, a higher prevalence of relatively high CHD risk  
4 was observed in the highest quintile (OR=2.12, 95%CI 1.18-3.80, P=0.012) of hs-CRP when comparing  
5 with the lowest quintile, and P for trend was 0.057. After adjustment for BMI, educational background,  
6 alcohol drinking status, activity level, serum creatinine and diabetes, the results did not change materially.  
7  
8 Though ORs of relatively high CHD risk were raised in subjects with higher serum hs-CRP level, only  
9 a not significant but borderline trend association was observed; the multivariable OR based on a  
10 comparison of the highest and the lowest quintile of hs-CRP was 2.10 (95% CI, 1.15-3.84; P=0.016),  
11 and P for trend was 0.068.

### 12 13 **Discussion**

14 The present cross-sectional study revealed a borderline positive association between hs-CRP and the  
15 high 10-year risk of CHD in the middle-aged and elderly population with hyperuricemia. This correlation  
16 didn't changed significantly with adjustment of several potential confounding factors such as BMI,  
17 educational background, alcohol drinking status, activity level, serum creatinine and diabetes. These  
18 findings suggested that hs-CRP could serve as a marker for the risk of CHD in hyperuricemia patients.

19  
20 The relationship between CRP and CHD has aroused intensive arguments. Some earlier studies  
21 demonstrated that a high level of CRP concentration was positively associated with CHD, and that CRP  
22 was predictive of CHD.<sup>34-37</sup> For example, in two nested case-control studies — the Nurses' Health Study

1 and the Health Professionals Follow-up Study — Jennifer et al. found that a high level of CRP was  
2 associated with an increased risk of CHD among participants with no history of cardiovascular disease  
3 and that the level of CRP could be considered as a predictor of CHD.<sup>38</sup> In the Cardiovascular Health  
4 Study, elevated CRP was found to be associated with an increased 10-year risk of CHD, regardless of  
5 the presence of conventional risk factors.<sup>39</sup> Besides, a cross-sectional study conducted in Japan  
6 demonstrated that hs-CRP was associated with the estimated risk level of CHD in the middle-aged men.<sup>40</sup>  
7 However, controversy remains with respect to the association of CRP with CHD, and the predictive value  
8 of CRP. According to the data obtained from the MONICA Optional Haemostasis Study, no significant  
9 correlation was observed between the CHD event rate and the plasma CRP in the European populations.<sup>41</sup>  
10 Similarly, it was shown that the CRP level was not significantly associated with CHD with adjustment  
11 of conventional risk factors in the post-menopausal women.<sup>42</sup> Meanwhile, the findings from the 1999–  
12 2004 NHANES suggested that hs-CRP was not associated with the CHD mortality.<sup>43</sup> The present study  
13 further revealed that CRP was borderline positively associated with CHD in patients with hyperuricemia.

14  
15 It is interesting that, in the present study, the OR for CHD risk was lower in the highest quintile  
16 than the fourth quintile of hs-CRP. This phenomenon was also observed in several previous studies.  
17 Folsom et al. showed that the multivariate-adjusted relative risk of CHD in the fifth quintile of CRP was  
18 lower than in the fourth quintile.<sup>44</sup> Similar result was observed in another study which demonstrated that  
19 multivariate-adjusted relative risk of cardiovascular events was lower in the fourth quartile than in the  
20 third quartile of CRP.<sup>45</sup> However, our study and these previous studies are all epidemiologic studies  
21 which cannot establish mechanisms, and additional basic research on this interesting phenomenon is  
22 needed.

1  
2  
3  
4 1  
5  
6 2 Previous in vivo and in vitro studies have suggested that CRP modulated many factors involved in  
7  
8  
9 3 atherosclerosis, which might explain the positive association between the CRP level and CHD. CRP  
10  
11  
12 4 could reduce the endothelial nitric oxide synthase both at the protein and mRNA levels and promote the  
13  
14  
15 5 production of inducible nitric oxide synthase and endothelin-1 in endothelial cells.<sup>38 39</sup> Besides, it was  
16  
17  
18 6 reported that the adhesion and internalization of white blood cells onto the arterial wall were improved  
19  
20  
21 7 by CRP by inducing the expression of vascular cell adhesion molecule-1, intercellular adhesion  
22  
23  
24 8 molecule-1, E-selectin, and monocyte chemoattractant protein-1.<sup>46 47</sup> Moreover, CRP could also induce  
25  
26  
27 9 the monocyte chemotaxis and differentiation,<sup>48 49</sup> and facilitate the uptake of oxidized low-density  
28  
29  
30 10 lipoprotein through macrophages and monocyte-platelets aggregation.<sup>50 51</sup> Further evidence supported  
31  
32  
33 11 CRP as a participant in later stages of atherosclerosis with the expression of matrix metalloproteinases  
34  
35  
36 12 and collagenase activity in human monocyte-macrophages.<sup>52 53</sup>

37  
38 14 The present study clarified that high hs-CRP was correlated with a high CHD risk in the middle-  
39  
40  
41 15 aged and elderly population with hyperuricemia, while several previous study have shown that CRP was  
42  
43  
44 16 not significantly associated with CHD in general population or other population.<sup>24 42</sup> It is suggested that  
45  
46  
47 17 hyperuricemia interacts synergistically with high hs-CRP subjects, and may subsequently enhance the  
48  
49  
50 18 risk of CHD predictor value of hs-CRP. This has implications for clinicians to predict the CHD risk in  
51  
52  
53 19 hyperuricemia patients based on hs-CRP, an easily measured clinical marker, and thereby providing  
54  
55  
56 20 preventive measures accordingly. Meanwhile, it also prompts that uric acid may interact with other risk  
57  
58  
59 21 factors during the development and progression of CHD, but such conclusion needs to be validated by  
60  
22 further study.

1  
2  
3  
4 1  
5  
6 2  
7 Several strengths and shortcomings of this study are worth being mentioned. First, this is the first  
8  
9 3  
10 study exploring the association between hs-CRP and the CHD risk in patients with hyperuricemia in the  
11  
12 4  
13 middle-aged and elderly population. Second, multivariable models were used to analyze the  
14  
15 5  
16 aforementioned relationship by adjusting a considerable number of potential confounding factors, such  
17  
18 6  
19 as BMI, serum creatinine and diabetes. As for the limitations, first, no causal relationship can be  
20  
21 7  
22 established in the present study due to the nature of cross-sectional design. However, the primary  
23  
24 8  
25 objective of this study was to examine the association between CRP and the CHD risk rather than to  
26  
27 9  
28 prove that CRP could increase the incidence of CHD. As CRP was deemed to be correlated with the  
29  
30 10  
31 CHD risk score, it can be used to reflect this complicated index in clinical practice. Subsequently, other  
32  
33 11  
34 more complicated indexes such as the Framingham risk score could be used to examine the CHD risk.  
35  
36 12  
37 Therefore, it can be speculated that CRP may have the potential to be an easily accessible screening  
38  
39 13  
40 method in the future after further studies' confirmation. Second, though FRS has been used to assess the  
41  
42 14  
43 risk of cardiovascular events in Chinese population,<sup>54 55</sup> it is noteworthy that FRS was originally  
44  
45 15  
46 constructed for the US population using a US population data. Third, age, sex, blood pressure, cholesterol  
47  
48 16  
49 and smoking should be included in adjusting covariates in multivariate analyses regarding CHD risk.  
50  
51 17  
52 However, FRS was calculated based on seven risk factors: age, gender, smoking, systolic blood pressure,  
53  
54 18  
55 use of antihypertensive medication, total cholesterol and HDL cholesterol. Therefore, we excluded these  
56  
57 19  
58 impotent confounders from adjusting risk factors as previous studies did.<sup>56 57</sup>  
59  
60 20

## 21 **Conclusion**

22 This study showed that ORs of relatively high 10-year CHD risk were raised in hyperuricemia patients

1 with higher serum hs-CRP level, however, there was a not significant but borderline trend association  
2 and that more research is needed.

3  
4 **Contributors** MX, DX, HL and XD were responsible for the conception and design of the study. KL,  
5 BZ and ZY contributed to the statistical analyses. MX, DX, HL, XD, YY and YZ contributed to the data  
6 collection and interpretation. MX, DX, HL and XD drafted the manuscript. HL, XD and ZY contributed  
7 to the revision of the manuscript. All authors read and approved the final manuscript.

8 **Funding** This work was supported by the National Natural Science Foundation of China (81772413,  
9 81702207, 81702206), the Young Investigator Grant of Xiangya Hospital, Central South University  
10 (2017Q10), and the Postgraduate Independent Exploration and Innovation Project of Central South  
11 University (2018zzts256).

12 **Competing interests** None declared.

13 **Patient consent** Not required.

14 **Ethics approval** This study was approved by the ethics committee of Xiangya Hospital, Central South  
15 University.

16 **Data sharing statement:** No additional data available.

1  
2  
3  
4 15  
6 2 **References:**

- 7  
8 3 1. Hak AE, Choi HK. Lifestyle and gout. *Curr Opin Rheumatol* 2008;20:179-86.
- 9  
10 4 2. Zhai FY, He YN, Ma GS, *et al.* [Study on the current status and trend of food consumption among  
11 Chinese population]. *Chinese Journal of Epidemiology* 2005;26:485.
- 12  
13 5 3. Liu R, Han C, Wu D, *et al.* Prevalence of Hyperuricemia and Gout in Mainland China from 2000  
14 to 2014: A Systematic Review and Meta-Analysis. *Biomed Res Int* 2015;2015:1-12.
- 15  
16 7 4. Onat A, Uyarel H, Hergenç G, *et al.* Serum Uric Acid Is a Determinant of Metabolic Syndrome in  
17 a Population-Based Study. *Am J Hypertens* 2006;19:1055-62.
- 18  
19 9 5. Oda E. Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health  
20 screening population. *Heart & Vessels* 2014;29:496-503.
- 21  
22 11 6. Iseki K, Ikemiya Y, Inoue T, *et al.* Significance of hyperuricemia as a risk factor for developing  
23 ESRD in a screened cohort. *Am J Kidney Dis* 2004;44:642-50.
- 24  
25 12 7. Chang HY, Tung CW, Lee PH, *et al.* Hyperuricemia as an independent risk factor of chronic kidney  
26 disease in middle-aged and elderly population. *Am J Med Sci* 2010;339:509-15.
- 27  
28 14 8. Li M, Hou W, Zhang X, *et al.* Hyperuricemia and risk of stroke: a systematic review and meta-  
29 analysis of prospective studies. *Atherosclerosis* 2014;232:265-70.
- 30  
31 16 9. Lai X, Yang L, Légaré S, *et al.* Dose-response relationship between serum uric acid levels and risk  
32 of incident coronary heart disease in the Dongfeng-Tongji Cohort. *Int J Cardiol* 2016;224:299-304.
- 33  
34 18 10. Braga F, Pasqualetti S, Ferraro S, *et al.* Hyperuricemia as risk factor for coronary heart disease  
35 incidence and mortality in the general population: a systematic review and meta-analysis. *Clinical*  
36  
37 19 11. Kim SY, Guevara JP, Kim KM, *et al.* Hyperuricemia and coronary heart disease: A systematic  
38  
39 20 12. Coutinho TDA, Turner ST, Peyser PA, *et al.* Associations of Serum Uric Acid With Markers of  
40  
41 21 Inflammation, Metabolic Syndrome, and Subclinical Coronary Atherosclerosis. *Am J Hypertens*  
42  
43 22 2007;20:83-9.
- 44  
45 23 13. Perlstein TS, Gumieniak O, Williams GH, *et al.* Uric Acid and the Development of Hypertension  
46  
47 24 The Normative Aging Study. *Hypertension* 2006;48:1031-6.
- 48  
49 25 14. Li Q, Yang Z, Lu B, *et al.* Serum uric acid level and its association with metabolic syndrome and  
50  
51 26 carotid atherosclerosis in patients with type 2 diabetes. *Cardiovasc Diabetol* 2011;10:1-7.
- 52  
53 27 15. Masuo K, Kawaguchi H, Mikami H, *et al.* Serum uric acid and plasma norepinephrine  
54  
55 28  
56 29  
57 30  
58 31  
59 32  
60

- 1 concentrations predict subsequent weight gain and blood pressure elevation. *Hypertension* 2003;42:474-  
2 80.
- 3 16. Nakanishi N, Okamoto M, Yoshida H, *et al.* Serum Uric Acid and Risk for Development of  
4 Hypertension and Impaired Fasting Glucose or Type II Diabetes in Japanese Male Office Workers. *Eur*  
5 *J Epidemiol* 2003;18:523-30.
- 6 17. Dehghan A, Hoek MV, Sijbrands EJG, *et al.* High Serum Uric Acid as a Novel Risk Factor for  
7 Type 2 Diabetes. *Diabetes Care* 2008;31:361-2.
- 8 18. Rathmann W, Funkhouser E, Dyer AR, *et al.* Relations of hyperuricemia with the various  
9 components of the insulin resistance syndrome in young black and white adults: the CARDIA study.  
10 Coronary Artery Risk Development in Young Adults. *Ann Epidemiol* 1998;8:250-61.
- 11 19. Khosla UM, Zharikov S, Finch JL, *et al.* Hyperuricemia induces endothelial dysfunction. *Kidney*  
12 *Int* 2005;67:1739-42.
- 13 20. Lloyd-Jones. Heart Disease and Stroke Statistics-2009 Update: A Report From the American Heart  
14 Association Statistics Committee and Stroke Statistics Subcommittee (vol 119, pg e21, 2009).  
15 *Circulation* 2011;124:E424.
- 16 21. Libby P, Sukhova G, Lee RT, *et al.* Cytokines regulate vascular functions related to stability of the  
17 atherosclerotic plaque. *J Cardiovasc Pharmacol* 1995;25 Suppl 2:S9.
- 18 22. Ross R. Atherosclerosis-inflammatory disease. *N Engl J Med* 1999;340
- 19 23. Savve VD, Ushakov GS. C-reactive protein, a sensitive marker for inflammation, predicts future  
20 risk of coronary heart disease in initially healthy middle-aged men: Koenig W, Sund M, Frohlich M, *et*  
21 *al.*: *Circulation* 99: 237 - 242, 1999. *Zhurnal Mikrobiologii Epidemiologii I Immunobiologii* 1962;33:15-  
22 20.
- 23 24. Yarnell J, Mccrum E, Rumley A, *et al.* Association of European population levels of thrombotic  
24 and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study  
25 †. *Eur Heart J* 2005;26:332-42.
- 26 25. Otsuka T, Kawada T, Katsumata M, *et al.* High-sensitivity C-reactive protein is associated with the  
27 risk of coronary heart disease as estimated by the Framingham Risk Score in middle-aged Japanese men.  
28 *Int J Cardiol* 2008;129:245-50.
- 29 26. Danesh J, Wheeler JG, Hirschfield GM, *et al.* C-reactive protein and other circulating markers of  
30 inflammation in the prediction of coronary heart disease. *Acc Current Journal Review* 2004;13:27-8.
- 31 27. Zeng C, Li H, Wei J, *et al.* Association between Dietary Magnesium Intake and Radiographic Knee  
32 Osteoarthritis. *Plos One* 2015;10:e127666.
- 33 28. Zeng C, Wei J, Li H, *et al.* Relationship between Serum Magnesium Concentration and



- 1 Radiographic Knee Osteoarthritis. *J Rheumatol* 2015;42:1231-6.
- 2 29. Zeng C, Wang YL, Wei J, *et al.* Association between low serum magnesium concentration and  
3 hyperuricemia. *Magnesium Research Official Organ of the International Society for the Development of*  
4 *Research on Magnesium* 2015;28:56.
- 5 30. Xie DX, Xiong YL, Zeng C, *et al.* Association between low dietary zinc and hyperuricaemia in  
6 middle-aged and older males in China: a cross-sectional study. *Bmj Open* 2015;5:e8637.
- 7 31. Xiong Y, Wei J, Zeng C, *et al.* Association between dietary iron intake and bone mineral density:  
8 A cross-sectional study in Chinese population. *Nutr Diet* 2016;73:433-40.
- 9 32. Li H, Zeng C, Wei J, *et al.* Associations between dietary antioxidants intake and radiographic knee  
10 osteoarthritis. *Clin Rheumatol* 2016;35:1585-92.
- 11 33. Program NCE. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel  
12 on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel  
13 III) final report. *Circulation* 2002;106:3143-421.
- 14 34. Cushman M, Arnold AM, Psaty BM, *et al.* C-reactive protein and the 10-year incidence of coronary  
15 heart disease in older men and women: the cardiovascular health study. *Circulation* 2005;112:25-31.
- 16 35. Straczek C, Ducimetiere P, Barbergergateau P, *et al.* Higher level of systemic C-reactive protein is  
17 independently predictive of coronary heart disease in older community-dwelling adults: the three-city  
18 study. *J Am Geriatr Soc* 2010;58:129-35.
- 19 36. Danesh J, Wheeler JG, Hirschfield GM, *et al.* C-reactive protein and other circulating markers of  
20 inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004;350:1387-97.
- 21 37. Kaptoge S, Angelantonio ED, Lowe G, *et al.* C-reactive protein concentration and risk of coronary  
22 heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* 2010;375:132-40.
- 23 38. Venugopal SK, Devaraj S, Yuhanna I, *et al.* Demonstration That C-Reactive Protein Decreases  
24 eNOS Expression and Bioactivity in Human Aortic Endothelial Cells. *Circulation* 2002;106:1439-41.
- 25 39. Verma S, Li SH, Badiwala MV, *et al.* Endothelin antagonism and interleukin-6 inhibition attenuate  
26 the proatherogenic effects of C-reactive protein. *Circulation* 2002;105:1890.
- 27 40. Otsuka T, Kawada T, Katsumata M, *et al.* High-sensitivity C-reactive protein is associated with the  
28 risk of coronary heart disease as estimated by the Framingham Risk Score in middle-aged Japanese men.  
29 *Int J Cardiol* 2008;129:245.
- 30 41. Yarnell J, Mccrum E, Rumley A, *et al.* Association of European population levels of thrombotic  
31 and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study.  
32 *Eur Heart J* 2005;26:332-42.
- 33 42. Kim HC, Greenland P, Rossouw JE, Manson JE, *et al.* Multimarker prediction of coronary heart

- 1 disease risk: the Women's Health Initiative. *J Am Coll Cardiol* 2010;55:2080-91.
- 2 43. Veeranna V, Zalawadiya SK, Panaich S, *et al.* Comparative analysis of red cell distribution width  
3 and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic  
4 population: findings from the 1999-2004 NHANES. *Int J Cardiol* 2013;168:5156-61.
- 5 44. Folsom AR, Aleksic N, Catellier D, *et al.* C-reactive protein and incident coronary heart disease in  
6 the Atherosclerosis Risk In Communities (ARIC) study. *Am Heart J* 2002;144:233-8.
- 7 45. Schulze MB, Rimm EB, Li T, *et al.* C-reactive protein and incident cardiovascular events among  
8 men with diabetes. *Diabetes Care* 2004;27:889-94.
- 9 46. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human  
10 endothelial cells. *Circulation* 2000;102:2165-8.
- 11 47. Pasceri V, Cheng JS, Willerson JT, *et al.* Modulation of C-reactive protein-mediated monocyte  
12 chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. *Circulation*  
13 2001;103:2531-4.
- 14 48. Torzewski M, Rist C, Mortensen RF, *et al.* C-reactive protein in the arterial intima: role of C-  
15 reactive protein receptor-dependent monocyte recruitment in atherogenesis. *Arteriosclerosis Thrombosis*  
16 *& Vascular Biology* 2000;20:2094.
- 17 49. Zhang R, Becnel L, Li M, *et al.* C-reactive protein impairs human CD14+ monocyte-derived  
18 dendritic cell differentiation, maturation and function. *Eur J Immunol* 2006;36:2993-3006.
- 19 50. Chang MK, Binder CJ, Torzewski M, *et al.* C-reactive protein binds to both oxidized LDL and  
20 apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids.  
21 *P Natl Acad Sci Usa* 2002;99:13043-8.
- 22 51. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake  
23 by macrophages: implications for atherosclerosis. *Circulation* 2001;103:1194-7.
- 24 52. Williams TN, Zhang CX, Game BA, *et al.* C-Reactive Protein Stimulates MMP-1 Expression in  
25 U937 Histiocytes Through Fc  $\gamma$  RII and Extracellular Signal-Regulated Kinase Pathway: An Implication  
26 of CRP Involvement in Plaque Destabilization. *Arterioscler Thromb Vasc Biol* 2004;24:61-6.
- 27 53. Nabata A, Kuroki M, Ueba H, *et al.* C-reactive protein induces endothelial cell apoptosis and matrix  
28 metalloproteinase-9 production in human mononuclear cells: Implications for the destabilization of  
29 atherosclerotic plaque. *Atherosclerosis* 2008;196:129.
- 30 54. Lu J, Bi Y, Wang T, *et al.* The relationship between insulin-sensitive obesity and cardiovascular  
31 diseases in a Chinese population: results of the REACTION study. *Int J Cardiol* 2014;172:388-94.
- 32 55. Tay YH, Nurjono M, Lee J. Increased Framingham 10-year CVD risk in Chinese patients with  
33 schizophrenia. *Schizophr Res* 2013;147:187-92.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 56. Maluf CB, Barreto SM, Dos RR, *et al.* Platelet volume is associated with the Framingham risk score  
2 for cardiovascular disease in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). *Clin Chem*  
3 *Lab Med* 2016;54:879-87.

4 57. Ebrahimof S, Hosseini-Esfahani F, Mirmiran P, *et al.* Food Patterns and Framingham Risk Score  
5 in Iranian Adults: Tehran Lipid and Glucose Study: 2005-2011. *Metab Syndr Relat Disord* 2018;16:64-71.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Table 1 Basic characteristics of study population based on the quintiles of hs-CRP level (n=517)

Characteristics	Quintiles of hs-CRP (mg/L)					P for trend
	1 (≤0.50)	2 (0.51-0.90)	3 (0.91-1.63)	4 (1.64-3.04)	5 (≥3.05)	
N	108	99	106	100	104	
<b>Demographic characteristics</b>						
Age (years)	50.2 (6.6)	50.2 (5.6)	51.3 (7.3)	51.4 (6.0)	51.5 (7.4)	0.165
Female (%)	13.0	13.1	13.2	19.0	18.3	0.206
Educational background (High school or above, %)	66.7	53.5	75.5	66.0	62.5	0.743
<b>Clinical characteristics</b>						
BMI (kg/m <sup>2</sup> )	25.3 (3.2)	26.0 (2.6)	26.8 (3.1)	26.8 (3.0)	27.0 (3.6)	0.001
Relatively high CHD risk (≥10%, %)	25.0	32.3	40.6	48.0	41.3	0.057
Systolic blood pressure (mmHg)	129.4 (14.3)	132.7 (15.7)	133.6 (15.5)	135.6 (16.9)	136.3 (17.4)	0.873
Diastolic blood pressure (mmHg)	82.1 (11.0)	84.3 (11.5)	85.1 (11.3)	86.3 (11.6)	87.5 (12.2)	0.151
Diabetes (yes, %)	12.0	12.1	11.3	18.0	17.3	0.174
<b>Biochemical characteristics</b>						
Total cholesterol (mg/dl)	202.8 (35.6)	209.1 (37.9)	207.8 (40.9)	211.1 (41.4)	206.7 (49.6)	0.873
HDL cholesterol (mg/dl)	53.2 (13.4)	51.6 (13.5)	51.8 (9.6)	50.7 (12.1)	49.5 (10.6)	0.151
Serum creatinine (μmol/L)	100.5 (32.8)	104.4 (49.7)	98.9 (14.9)	99.5 (34.9)	99.1 (17.6)	0.528
<b>Lifestyle characteristics</b>						
Activity level (h/week)	2.0 (2.5)	1.3 (2.3)	1.8 (2.9)	1.6 (2.7)	1.2 (2.3)	0.047
Smoking (yes, %)	24.1	29.3	34.9	36.0	35.6	0.165
Alcohol drinking (yes, %)	53.7	61.6	63.2	61.0	52.9	0.328

4 Data are mean (standard deviation), unless otherwise indicated; hs-CRP, hypersensitive C-reactive

1 protein; BMI, body mass index; HDL, high density lipoprotein.

2

3 Table 2 Associations between hs-CRP and relatively high 10-year CHD risk ( $\geq 10\%$ ) in  
4 hyperuricemia population (n=517)

		Quintiles of hs-CRP (mg/L)					P for trend
		1 ( $\leq 0.50$ )	2 (0.51-0.90)	3 (0.91-1.63)	4 (1.64-3.04)	5 ( $\geq 3.05$ )	
Participants (n)		108	99	106	100	104	
Median hs-CRP (mg/L)		0.34	0.69	1.21	2.11	6.12	
Crude OR (95%CI)		1.00 (reference)	1.43 (0.78, 2.63)	2.05 (1.14, 3.67)	2.77 (1.54, 4.98)	2.12 (1.18, 3.80)	0.057
P values		-	0.245	0.016	0.001	0.012	
Multivariable adjusted OR (95% CI)		1.00 (reference)	1.40 (0.75, 2.61)	2.05 (1.13, 3.72)	2.69 (1.47, 4.89)	2.10 (1.15, 3.84)	0.068
P values		-	0.291	0.019	0.001	0.016	

5 \*Multivariable adjusted model was adjusted for BMI, educational background, alcohol drinking  
6 status, activity level, serum creatinine and diabetes. hs-CRP, hypersensitive C-reactive protein;  
7 CHD, coronary heart disease; OR, odds ratio; CI, confidence interval.

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4,5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5, 6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5,6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7, 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7, 8
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	7,8

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	5, 6
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	19
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8,9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	19
		(b) Report category boundaries when continuous variables were categorized	20
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	20
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9,10,11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).